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ABSTRACT 
 
 
 This descriptive, correlational study investigated the associations among gastric 
myoelectrical activity (GMA), upper gastrointestinal (GI) symptoms, and glucose control. 
The study also attempted to determine whether any relationship existed between upper GI 
symptoms, glucose control, age, or length of diagnosis and pattern of GMA identified 
using electrogastrography (EGG).  
 A total of 25 persons participated in the study. The sample was comprised of 7 
healthy controls, 5 patients diagnosed with type 1 diabetes, and 13 patients diagnosed 
with type 2 diabetes. Demographic data, a health history, blood sampling, and assessment 
of historical and current upper GI symptoms were obtained. Electrogastrography was 
performed for 30 minutes in the fasting state and continued at 30-minute intervals for a 
total of 1-1/2 hours post-prandially. Data from the fasting, 30-minute post-prandial 
period, and 120-minute post-prandial periods were analyzed for the study.   
 For research question one, non-significant p values were confirmed during fasting 
(p = .14) and 120-minutes post-prandial (p = .11). A significant p value was noted at 30-
minutes post-prandial (p = .04). This suggests that no difference exist between patterns of 
GMA in healthy subjects and patients with diabetes except during the period immediately 
after eating. No significant differences in the pattern of GMA were identified in type 1 
versus type 2 diabetic patients during any sampling period (p = .81, .49, and .88, 
respectively).  
Research question 2 looked at GMA during 3 periods. At the end of the fasting 
period (period 1), there were 7 patients with normogastria, 10 with bradygastria, and 1 
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with tachygastria. The bradygastric group reported greater mean scores for symptom 
presence and severity historically and during the fasting period on all upper GI signs and 
symptoms. During period 1, mean scores for satiety on the TSS scale were the only 
variable yielding any significant result (p = .04). For this sample, no relationship was 
found between the three patterns of GMA and acute blood glucose, metabolic control, 
age, or length of diagnosis in patients with diabetes who were fasting. During the first 
post-prandial period (30 minutes post meal; period 2), 4 subjects were normogastric, 7 
were bradygastric, and 7 were tachygastric. There were no significant differences found 
between the distributions of scores for the variables under study and patterns of GMA. 
During the 120-minute post prandial period (period 5), 6 subjects were normogastric, 7 
were bradygastric, and 5 were tachygastric. There were no significant differences found 
between the distributions of mean scores for the variables under study and patterns of 
GMA. 
In conclusion, findings of this study support the potential use of EGG as a 
screening tool in the detection of patterns of GMA in healthy and diabetic individuals. 
Using EGG, gastric myoelectrical activity can be identified in both healthy controls and 
patients diagnosed with diabetes. Further studies are needed to generate data that can be 
used to explain the pathology behind, and relationship between GMA abnormalities, 
upper GI signs and symptoms, and the lack of glucose control in patients with diabetes. 
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CHAPTER 1.   INTRODUCTION 
 
Overview 
The gastrointestinal (GI) system has an underlying pattern of electrical activity 
much like the one in the cardiac system that controls its contractile and propulsive 
activity.  Gastric myoelectrical activity (GMA) originates in the body of the stomach and 
normally propagates toward the pylorus at a rate of three cycles per minute (cpm; 
Parkman, Hasler, Barnett, & Eaker, 2003). Changes in GMA affect gastric motility and 
gastric emptying.  The resulting dysfunction leads to alterations in the process of 
digestion.  These alterations are manifested as GI signs and symptoms such as nausea, 
vomiting, anorexia, early satiety, bloating, and abdominal pain. In persons with diabetes 
mellitus, altered GMA affects digestion of nutrients and drugs, further complicating the 
ability to achieve and maintain normoglycemia. Mismatches in circulating insulin and 
nutrient availability contribute to problems with maintaining glucose control and increase 
the progression of diabetes complications. The older the person with diabetes is and the 
longer the length of diagnosis, especially if poorly controlled, the more likely 
complications are to exist. These factors increase the burden of diabetes care and 
decrease the quality of life (QOL) of persons with diabetes. Identification of changes or 
abnormalities in patterns of GMA in relation to GI signs and symptoms, glucose control, 
age, and length of diagnosis could be used to direct interventions that could halt or retard 
the progression of diabetes complications and improve the QOL experienced by this 
population. 
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Patterns of GMA can be assessed using electrogastrography (EGG). 
Electrogastrography is a simple, noninvasive tool that can be used to provide valid 
information about changes in patterns of GMA prior to manifestations of actual signs and 
symptoms of altered function. Electrogastrography captures GMA cutaneously with little 
preparation, is more comfortable, and less burdensome for patients than other test of GI 
function. The tool is easy to use and requires only a short period to obtain data. Although 
it has been available for some time, EGG has developed relatively slowly since its first 
application by Alvarez (1922) in 1921. Difficulty in overcoming problems related to 
capturing and analyzing data had to wait until technological advances could provide more 
valid and reliable data. Continued study of the GI system and improvements in 
biomedical instrumentation, have increased EGG’s ability to distinguish patterns of GMA 
in healthy individuals from those with certain diseases or conditions (Chen, Lin, 
Sarosiek, & McCallum, 1996; Familoni, 1994; Kim, Ming, & Camilleri, 2000; 
Pfaffenbach, Adamek, Kuhn, & Wegener, 1995; Sanmiguel, Mintchev, & Bowes, 1998). 
Examining EGG patterns of GMA in specific disease states will help to determine the 
clinical utility of EGG. For these reasons, the present study focuses on examining the 
ability of EGG to detect GMA and correlating EGG results with upper GI signs and 
symptoms, acute blood glucose levels, and long-term metabolic control in patients with 
diabetes mellitus. The use of EGG in the clinical setting may provide diagnostic 
information that can assist in identifying pathology behind problems with gastric 
function. Electrogastrography can also be used for monitoring GMA and has the potential 
for determining abnormalities that may precede serious complications of diabetes, 
providing time to develop and institute specific treatment options. 
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Studies over the past 20 years evaluating GMA in persons with diabetes have 
yielded key information as well as conflicting results. Some investigators report 
significant relationships between or among gastric rhythm, symptom presence, and level 
of metabolic control (Cucchiara et al., 1998; Koch, Stern, Stewart, & Vasey, 1989; 
Mantides et al., 1997; Mayaudon et al., 1999; Soykan, Lin, Sarosiek, & McCallum, 1999) 
in persons with type 1 diabetes. Results of studies of GMA in persons with type 2 
diabetes (Gad-el-Hak & Baker, 2001; Mathur, et al, 2001; Qi, Luo, & Wang, 2002) 
provided additional insight and knowledge into the complexity of GMA, GI symptoms, 
and metabolic control in this group of patients. Other studies (El-Salhy & Sitohy, 2001; 
Jebbink et al., 1994; Pfaffenbach et al., 1995) were unable to distinguish significant 
differences in gastric rhythm, symptoms, and blood glucose measures between persons 
with type 1 or type 2 diabetes and healthy controls. Methods used to study gastric 
dysrhythmias and their relationship to gastric symptoms and metabolic control in patients 
with diabetes have not been performed consistently. This pilot study seeks to assess and 
describe patterns of GMA in patients with diabetes mellitus controlling for multiple 
variables, and to determine if specific patterns of GMA correspond with upper GI signs 
and symptom presence and severity, acute blood glucose levels, long-term glucose 
(metabolic) control, age, or length of diagnosis in patients with diabetes mellitus. 
 
Statement of the Problem 
A large percentage of patients with diabetes report an increased incidence of GI 
signs and symptoms and inability to gain and/or maintain glucose control. Alterations in 
the digestive process contribute to these problems. Electrical, neuronal, and chemical 
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(hormonal) mechanisms must work in concert for digestion to occur normally. Because 
of the complexity of the digestive process, and inconsistencies in previous studies, further 
research under controlled conditions is needed to identify the relationship between GMA, 
GI signs and symptoms, glucose control, age and length of diagnosis, and to determine 
the actual significance of the information obtained. Therefore, this study was proposed. 
 
 
Purpose of the Study 
The purpose of this pilot study was to assess and describe GMA in patients with 
diabetes mellitus using EGG. Additionally, the study sought to determine if specific 
patterns of activity corresponded with levels of symptom presence and severity, acute 
blood glucose levels, level of long-term metabolic control, age, or length of diagnosis 
during specific periods during the digestive process. This study’s results were based on 
findings made during the fasting, 30-minutes post prandial, and 120-minutes post 
prandial periods. 
 
Specific Aims 
Specific aims of this study were to 1) characterize the pattern of GMA in patients 
with diabetes, and 2) describe the relationships among patterns of GMA, symptom 
presence and severity, acute blood glucose level, long-term metabolic control, age, and 
length of diagnosis in patients with diabetes. 
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Research Questions  
Two research questions were addressed by the present study: 
1.   Research Question 1:  What patterns of GMA can be assessed using EGG in 
patients with diabetes? 
1a. What are the differences in patterns of GMA in healthy individuals versus 
diabetic patients?  
1b. What are the differences in patterns of GMA in patients with type 1 versus 
type 2 diabetes? 
2.   Research Question 2:  What is the relationship of patterns of GMA with upper GI 
symptoms, acute blood glucose measurement, metabolic control, age, and length 
of diagnosis in patients with diabetes mellitus? 
2a. What is the relationship of patterns of GMA with upper GI symptoms, acute 
blood glucose measurement, metabolic control, age, and length of diagnosis 
in patients with diabetes mellitus who are fasting? 
2b. What is the relationship of patterns of GMA with upper GI symptoms, acute 
blood glucose measurement, metabolic control, age, and length of diagnosis 
in patients with diabetes mellitus who are 30 minutes post-prandial? 
2c. What is the relationship of patterns of GMA with upper GI symptoms, acute 
blood glucose measurement, metabolic control, age, and length of diagnosis 
in patients with diabetes mellitus who are 120 minutes post-prandial? 
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Conceptual Framework 
A conceptual framework serves three important purposes:  it clarifies the concepts 
on which the study is built, identifies and states assumptions underlying the study, and 
specifies relationships among concepts (Woods & Cantanzaro, 1988). The conceptual 
framework (Figure 1) proposed in this study provided structure and guided the 
organization of the study.  
Diabetes mellitus is a complicated disease, requiring a comprehensive treatment 
plan that includes provider and patient contributions, in order to achieve the goals of 
establishing good metabolic control, reducing complications, and maintaining an 
acceptable QOL. Complications of diabetes arise as a result of persistently high blood 
glucose levels, a factor that can be treated effectively (Davidson, 1998; Huether & 
Tomkey, 1997; Kahn & Porte, 1997; Krall & Beaser, 1989; Palmer & Lenmark, 1997). 
Maintenance of glucose control is one of the most important aspects of diabetes care. 
Acute blood glucose levels must be kept at normal, or near normal levels, in order to 
achieve consistent overall metabolic control. Despite following the prescribed regime, 
some individuals are still unable to gain adequate metabolic control. Changes in the 
normal digestive pattern occurring in 30% to 50% of patients with diabetes, may 
contribute to, as well as result in, problems with maintaining metabolic control (Enck & 
Frieling, 1997; Horowitz & Fraser, 1994; Horowitz, Wishart, Jones, & Hebbard, 1996; 
Koch, 1999; Rothstein, 1990). In those diabetic patients who experience changes in 
digestive activity, symptoms reflecting alterations in normally coordinated movement of 
nutrients through the GI tract such as nausea, vomiting, abdominal pain, anorexia, early  
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Gastric Myoelectrical 
Activity 
Chronic Blood 
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of Upper 
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& Symptoms 
Figure 1. Relationships among Gastric Myoelectrical Patterns, Acute and 
Chronic Blood Glucose Levels, and Upper Gastrointestinal Signs and Symptoms 
in Patients with Diabetes Mellitus 
Note. 
 Factors contributing to diabetes complications. 
 Indicates uncertain strength of relationship. 
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satiety, or bloating, usually occur (Enck & Frieling, 1997; Horowitz & Fraser, 1994; 
1995; Horowitz, Wishart, Jones, & Hebbard, 1996; Koch, 1999; Kong, Macdonald, & 
Tattersall, 1996; Rothstein, 1999). Up to 76% of patients with diabetes in some reports, 
complain of these upper GI symptoms (Enck & Frieling, 1997; Horowitz & Fraser, 1995; 
Horowitz, Wishart, Jones, & Hebbard, 1996; Kong, Macdonald, & Tattersall, 1996),  
which appear to be associated with acute changes in blood glucose levels (hypo- and 
hyperglycemia), and altered patterns of GMA (Enck & Frieling, 1997; Kong, Macdonald, 
& Tattersall, 1996; Rothstein, 1999). Studies report that subjects with acute 
hyperglycemia experience more tachygastria, while subjects with chronically elevated 
blood glucose levels were more likely to be bradygastric (Mathur, et al., 2001; Jebbink, et 
al., 1994). Subjects with abnormal EGGs experienced greater GI signs and symptoms in 
some studies, but other studies report no relationship between GMA and GI signs and 
symptoms (Soykan, Lin, Sarosiek, & McCallum, 1999; Pfaffenbach, et al., 1995). 
Additional factors contribute to digestive problems in patients with diabetes, 
including length of diagnosis, age, gender, meal composition, and other conditions or 
diseases. The longer a person has diabetes, the more likely complications will exist 
(Davidson, 1998; Krall & Beaser, 1989). Poor metabolic control and the effects of 
diabetes throughout the body inhibit the ability to compensate for changes occurring due 
to altered glucose metabolism. Micro- and macrovascular changes affect each organ 
system. Progressive loss of beta cell function, or lack of insulin sensitivity, reduces the 
body’s ability to accommodate acute blood glucose changes. Nervous system 
degeneration is inevitable in persons’ with long-term loss or lack of glucose control 
(American Diabetes Association [ADA], 2003; Joslin, 2001; National Institute of 
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Diabetes & Digestive & Kidney Diseases [NIDDK], 2003).  The age at onset of diabetes 
is important. Younger individuals may experience greater complications in later life. 
During puberty, persons with type 1 diabetes experience abnormalities in the growth 
hormone/insulin-like growth factor-1 (GH/IGF-1) axis that leads to a reduction in insulin 
sensitivity (Acerini, Williams, & Dunger, 2001). Susceptibility to develop complications 
is greater during the pubescent growth spurt. Altered GH/IGF-1 levels have been 
implicated in the long-term complications associated with diabetes (Holly, Amiel, 
Sandhu, Rees, & Wass, 1988). These abnormalities are linked to deterioration in glucose 
control, especially in females. 
Diabetes affects gender nearly equally. Of the 20.6 million Americans aged 20 
years or older with diabetes, 10.9 million are men, and 9.7 million are women (NIDDK, 
2003). The rates of complications for patients with diabetes do vary by gender (Jones, 
Russo, Stevens, Wishart, Berry, & Horowitz, 2001). Women typically seek medical 
attention more frequently than men, and they experience more GI symptoms and 
depression (Schvarcz, Palmer, Ingberg, Aman, & Berne, 1996; Soykan, Sivri, Sarosiek, 
Kiernan, & McCallum, 1998).   
The process of digestion relies on the systematic processing of nutrients and 
drugs. The GI system’s activity is coordinated based upon the composition or type of the 
meal consumed, along with its volume. High fat or fiber meals require more time to 
complete the digestive process (Levanon, Zhang, Orr, & Chen, 1998; NIDDK, 2003). 
Regulation and feedback mechanisms work together to ensure that digestion occurs at the 
appropriate rate and fashion to extract useful products from the substance ingested and to 
excrete those products that are not needed. When these mechanisms do not work as they 
 10
should, GI symptoms exist, the person cannot properly process nutrients and drugs, and 
there is a mismatch in glucose-insulin utilization. This leads to more frequent hypo and/or 
hyperglycemic events in patients with diabetes and poor long-term metabolic control. 
Comorbid conditions contribute to digestive problems including the presence of 
neurological disease or injury (e.g. Parkinson’s disease, spinal cord injury), eating 
disorders (e.g. anorexia, bulimia), smooth muscle disorders (amyloidosis, scleroderma), 
intestinal pseudo-obstruction, or post-surgical problems also affects gastric activity 
(Aspenall & Taylor-Robinson, 2002; NIDDK, 2003; Ogawa et al., 2004). Any damage to 
the nerves that assist in the coordination of gastric activity could alter function. These 
factors must be taken into account when assessing the presence and severity of GMA 
abnormalities and GI symptoms in patients with diabetes. 
 
Definition of Concepts 
 A lack of standardization exists within the literature for some of the concepts of 
interest for this study. Therefore, it is necessary to provide a theoretical and operational 
definition for each concept of the framework in order to establish a point of reference. 
Gastric Function.  The actions of the GI tract required to initiate and maintain the 
process of digestion (Thomas, 1997). It is directed by autonomic nervous system activity 
and chemical and hormonal feedback in the stomach for the purpose of receiving, mixing, 
and emptying nutrients into the small intestines for absorption, and finally into the large 
intestine for processing and removal of waste materials. This complex pattern of activity 
is initiated by the thought, smell, sight, or ingestion of nutrient materials. 
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Electrogastrography (EGG).  A noninvasive test used to evaluate gastric 
myoelectrical activity. Electrogastrography measures reflect the slow wave or baseline 
activity as well as changes in contractility that occurs within a period (Mintchev, 2000; 
Pfaffenbach, Adamek, Kuhn, & Wegener, 1995; Smout, Van Der Shee, & Grashus, 
1980). The normal EGG frequency has been reported between 2 to 4 cycles per minute 
(cpm), with a normal post-prandial increase in amplitude of 1mV (Bellahsene, Schimer, 
Updike, & McCallum, 1992; Familoni, Bowes, Kingma, & Cote, 1991; Mintchev, 2000; 
Pfaffenbach, Adamek, Kuhn, & Wegener, 1995). 
Patterns of Gastric Myoelectrical Activity (GMA).  The speed and rhythm of 
myoelectrical discharges emitted from neurons in the stomach and reflected as frequency 
waveforms on a tracing. In this study, patterns of GMA will be categorized as normal 
(frequencies between 2.7 – 3.2 cpm), bradygastric (frequencies less than or equal to 2.69 
cpm), tachygastric (frequencies greater than or equal to 3.21 cpm), or mixed dysrhythmic 
(a combination of bradygastria and tachygastria). These characterizations provide insight 
into the basic electrical rhythm of the stomach, as well as the strength and direction of the 
contractions that are present (Familoni, 1994; Mintchev, 2000). 
Upper Gastrointestinal (GI) Symptoms.  Subjective or objective indicators of 
some alteration in the normal digestive pattern experienced by an individual (Thomas, 
1997). Upper GI symptoms were assessed in this study globally using the Total Symptom 
Score (TSS) and individually using visual analog scales (VAS).  
The TSS is a 6-item questionnaire used to evaluate the presence and severity of 
upper gastrointestinal symptoms and their overall impact on the patient’s general health. 
Individual scores for each symptom on the TSS range from zero to 10, with higher scores 
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indicating greater symptom presence and severity. An overall summary score (Sum TSS) 
was also reported for the previous 2-month period.  
A 100mm VAS was used to assess the presence and severity of nausea, vomiting, 
pain, bloating, and early satiety experienced during the EGG testing procedure. A score 
of zero indicates no nausea, vomiting, pain, bloating, or early satiety, and a score of 100 
indicates the presence of severe symptoms. A detailed description of each symptom 
measured during this study follows. 
Nausea.  An unpleasant sensation usually felt when nerve endings in the stomach, 
or other areas, are irritated. It usually precedes vomiting and may be due to the site or 
odor of obnoxious matter or materials or mental images of the same (O’Toole, 1997; 
Thomas, 1997). 
Vomiting.  A reflexive phenomenon, which culminates with the forceful expulsion 
of gastric and/or intestinal contents through the mouth. Vomiting frequently occurs with 
nausea; however, it can occur with or without nausea (O’Toole, 1997; Thomas, 1997). 
Pain.  A sensation or feeling of distress, discomfort, or suffering caused by 
stimulation or irritation of sensory nerves (O’Toole, 1997; Thomas, 1997). The present 
study assessed pain presence/severity specifically over or in the abdomen. 
Anorexia.  The loss or lack of appetite (O’Toole, 1997; Thomas, 1997). 
Satiety.  Being full to satisfaction, especially with food (Thomas, 1997). 
Bloating.  A condition in which the abdomen feels full and tight or distended, 
usually caused by excessive intestinal gas (Thomas, 1997). 
Metabolic Control.  The level of long-term blood glucose control. As the 
hemoglobin in red blood cells travels through the blood stream, it acquires a glucose 
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coating or glycosylation. The higher the blood glucose, the more coating the cells 
acquire. Glycated (glycosolated) hemoglobin (GHB), measures the amount of coating the 
red cells have acquired over their lifetime, which spans 2 to 3 months. The results of this 
test will be reported as a glycosolated hemoglobin level percentage (%). Reference GHB 
is 4.2% to 7.0%. The glucose control index for near normal control is 7.0% to 8.0%; the 
range indicating good control is 8.0% to 9.0%; and a GHB level greater than 9.0% is an 
indication for action or intervention (Labcorp, 2001). The higher the GHB, the higher the 
risk that patients will develop complications from diabetes (eye disease, kidney disease, 
nerve damage, heart disease, and stroke) (Davidson, 1998; Krall & Beaser, 1989; 
NIDDK, 2003). 
Acute Blood Glucose.  Acute measurement of blood glucose levels. Fingerstick 
blood glucose monitoring (BGM) will be performed to assess acute changes in the 
circulating glucose during the EGG testing procedure. Information about immediate 
changes occurring in blood glucose levels relative to intake can be measured with this 
method (LifeScan, 2002). While acute changes in blood glucose levels may not affect the 
index for metabolic control (because of averaging of lows and highs over a 2-3 month 
period), these changes do affect GMA and the perception of symptoms during the episode 
(Barnett & Owyana, 1988; Jebbink et al., 1994). Recommended glycemic goals are 80-
120 mg/dl preprandially and average bedtime glucose of 100-140 mg/dl (ADA, 2003). 
Testing will be performed using a LifeScan One Touch Ultra monitoring device. This 
method of testing will be used to evaluate changes in the blood glucose levels pre- and 
post-prandially and provide data for assessing changes in patterns of GMA and upper GI 
symptoms and their severity as the blood glucose level changes. 
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Summary 
 The conceptual framework for this study guides the organization of the study. 
Within the framework, diabetes mellitus is a complex disease with multiple factors 
contributing to the inability to attain and maintain the level of glucose control necessary 
to reduce diabetes complications. The framework supports the argument that alterations 
in acute blood glucose levels contribute to changes in the body that perpetuate the 
inability to achieve long-term glucose control. Damage to the nervous system because of 
chronic or acute hyperglycemia contributes to change in the normal pattern of GMA. 
Changes in the normal pattern of GMA lead to digestive system alterations. Alterations in 
the digestive process affect acute and long-term blood glucose levels and predispose 
some patients to upper GI symptoms. The presence of GI symptoms may prohibit the 
patient from ingesting appropriate nutrients, while the alteration in the entire digestive 
process prohibits the normal processing of nutrients and drugs required to maintain 
metabolic control. The identification of factors that directly influence the ability to gain 
glucose control and the ability to describe relationships among patterns of GMA, 
symptom presence and severity, and metabolic control in patients with diabetes could be 
used to initiate, formulate, or monitor therapeutic interventions. 
 
Significance of the Study 
 The significance of this study lies in the contributions to further knowledge of 
GMA, pathophysiology of gastric function, and its relationship to GI symptoms in 
patients who are diagnosed with diabetes mellitus. Data obtained from this pilot study 
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provides additional validating information about changes in the patterns GMA, upper GI 
signs and symptoms, and level of glucose control, in patients with diabetes mellitus. 
An important issue in nursing and in healthcare in general, is the increasing 
prevalence of chronic conditions, such as diabetes. Reducing complications and 
enhancing adaptation for patients with diabetes can promote health and independence in 
this population. In the case of the patient with diabetes, identifying and understanding the 
role of patterns of GMA, the relationship to upper GI symptoms, and the maintenance of 
glucose control, provides information that can be used to help the healthcare provider 
plan strategies and treatments. Early and periodic testing of GMA using EGG can be 
instituted as a health promotion and evaluation strategy. Early identification and routine 
monitoring of changes in GMA in the patients with diabetes can direct treatments that 
will reduce upper GI symptoms and improve metabolic control, thereby reducing 
complications of diabetes mellitus. 
 
Assumptions 
 The following assumptions were made in this study: 
 
1. Transcutaneous EGG measures GMA. 
2. Secondary complications of diabetes mellitus, including alterations in the nervous 
system, occur because of poor metabolic control. 
3. An orderly, processional sequence of events, with appropriate inputs and 
feedback, must be maintained by the GI system in order for gastric function to 
occur normally. 
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4. Upper gastrointestinal symptoms occur as a result of alterations in gastric 
function. 
5. Gastric function is compromised because of altered patterns of GMA. 
6. Consistent, systematic processing of nutrients and drugs is required in order to 
achieve metabolic control. 
7. Normal, healthy controls will exhibit normal patterns of GMA, the absence of 
upper GI symptoms, and normal metabolic control. 
8. Clients will respond honestly and accurately to all questions during the testing      
session. 
 
Limitations 
 The following limitations of this study were identified: 
1.  There are no alternatives to the use of subjective tools to assess the presence and 
severity of upper GI symptoms. Self-report is the best means for measuring 
personal experiences with upper GI symptoms, which is a variable of interest in 
this study. The investigator must accept and believe the individual’s response to 
be honestly and accurately based upon the experience. Participants were 
encouraged to provide information based upon their individual assessment of the 
presence and severity of any symptom experienced. The investigator queried the 
participant and assisted with completing the tools without leading or prompting 
the individual’s response. 
2. Historical reporting of symptom presence and severity may not provide an 
accurate representation of the patient’s experience. Establishing a point of 
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comparison relative to other events or problems experienced by the individual 
may be difficult and become distorted over time. The idea that the person also 
becomes accustomed to certain levels of discomfort, and therefore no longer 
perceives it as disruptive, must be taken into account. The investigator directed 
the participant to select a response based upon the recollection of upper GI 
symptoms occurring during the previous 2-month period only. Comments or 
additional information provided which may have influenced symptoms were 
recorded on the subject’s data sheet. 
3. Electrogastrography only identifies patterns of GMA. Because of the complex 
nature of the process of digestion, this single measure may not definitively 
indicate altered gastric function. Additional measures, such as gastric emptying, 
weight changes, biochemical assessment of nutritional status, assessment of 
number of occurrence and volume of vomiting, etc., are not addressed in the 
present study. No diagnoses were made based upon the assessment of EGG data. 
Frequency measurements were categorized based upon established normative 
values and reported as such. 
4. Many clinical factors may be present that could affect this study, including certain 
comorbid diseases and conditions. Therefore, inclusion and exclusion criteria 
have been established to control for some of these variables. 
5. Results of this study cannot be generalized to samples of patients with other 
diseases and conditions whose pathology may affect gastric function by 
mechanisms other than those related to changes in GMA.  
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6. The Total Symptom Score (TSS) has been used in multiple studies by it authors, 
but standard reliability and validity information have not been established for this 
tool. 
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CHAPTER 2.  REVIEW OF LITERATURE 
 
Introduction 
 The pathological and physiological principles involved in the study of diabetes 
mellitus, gastric function, gastric complications, and gastric myoelectrical activity, are 
complex. A conceptual framework has been provided to assist in organizing the 
presentation of theoretical, clinical, and evidence-based literature related to the present 
study. This chapter will describe specific literature relevant to the following: 1) 
pathophysiology of diabetes mellitus, 2) principles of gastric function, 3) gastric 
complications in patients with diabetes and, 4) gastric myoelectrical activity and 
electrogastrography.  
 
Pathophysiology of Diabetes Mellitus 
 Diabetes is a syndrome of disordered metabolism with inappropriate 
hyperglycemia due to either an absolute deficiency of insulin secretion or a reduction in 
the biologic effectiveness of insulin (or both; Feingold & Funk, 2000; Greenspan & 
Gardner, 2001). Diabetes is a chronic disease that has no cure. It is the sixth leading 
cause of death due to disease in the United States and the third leading cause of death in 
some minority groups (ADA, 2003; Diabetes Research Working Group [DRWG], 1999; 
NIDDK, 2003). Diabetes is diagnosed using 3 criteria: 1) fasting plasma glucose ≥126 
mg/dl; 2) symptoms of diabetes plus a random plasma glucose ≥200 mg/dl; or 3) a 
plasma glucose level ≥200 mg/dl after an oral dose of 75g of glucose (glucose tolerance 
test; Feingold & Funk, 2000). There are different classifications of diabetes based upon 
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the etiology of the disease. The primary classifications include type 1 diabetes and type 2 
diabetes.  
Type 1 diabetes is caused by autoimmune destruction of insulin-producing beta 
cells in the Islets of Langerhans of the pancreas (DRWG, 1999). Persons with this form 
of diabetes must take insulin injections; without exogenous insulin, death is inevitable 
(DRWG, 1999). Type 1 diabetes accounts for 5% to 10% of all diagnosed cases of 
diabetes (ADA, 2003; NIDDK, 2003; Palmer & Lenmark, 1997); it usually occurs in 
childhood or adolescence (Feingold & Funk, 2000; Krall & Beaser, 1989; Palmer & 
Lenmark, 1997), but can occur at any age (DRWG, 1999). Evidence suggests that viral 
infections or toxic environmental insult may precipitate type 1 diabetes in a genetically 
predisposed person while an aggressive immune system destroys pancreatic beta cells in 
an attempt to overcome the invasive agent (Feingold & Funk, 2000; Marsharani & 
Karam, 2001).   
Type 2 diabetes differs from type 1 diabetes in that type 2 diabetes is believed to 
be caused by resistance to normal insulin action at the cellular level and by a relative 
reduction of insulin secretion (ADA, 2003). It is also linked to obesity, a factor that 
further increases insulin resistance (Feingold & Funk, 2000). Persons with this form of 
diabetes may take oral agents, which increase sensitivity to glucose or reduce insulin 
resistance. In some cases, persons with type 2 diabetes must take insulin injections. Type 
2 diabetes accounts for 90% to 95% of all diagnosed cases of diabetes (ADA, 2003; 
Feingold & Funk, 2000; Kahn & Porte, 1997; NIDDK, 2003).  
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Principles of Gastric Function 
The gastrointestinal (GI) system is the system responsible for taking in and 
processing nutrients and drugs required to sustain life. The entire process relies on the 
progression of ingested materials at the appropriate rate through the GI system. Ingested 
materials are propelled throughout the GI system by a series of coordinated contractions. 
The underlying mechanisms controlling gastric function are directed by a complicated 
system of neuronal, electrical, and chemical agents. The central nervous system, 
autonomic nervous system, enteric nervous system, and chemical (hormonal) controls 
work in conjunction to control the GI system (Camilleri & Prather, 1998; Falk, 1992; 
Goyal & Hirano, 1996; Lingappa, 2000; Redel & Zwiener, 1998; Wingate & Phillips, 
1998; Wood, 1998). Under the regulation of these systems, a number of processes are 
managed to ensure that ingested materials are moved through the GI system to complete 
the process of digestion.   
 The GI system is composed of several organs and accessory structures. These 
include the mouth, salivary glands, esophagus, stomach, liver, gall bladder, pancreas, 
small intestines, large intestines, rectum, and anus. Each organ has a specific purpose or 
function. The mouth ingests and begins to mechanically break down the foodstuff. Saliva 
is added as a lubricant. The esophagus acts as a conduit between the mouth and the 
stomach. In the stomach, acids are added to the composition and mixing occurs to further 
grind the materials into liquid form. The liver, gall bladder, and pancreas secrete 
additional chemicals and enzymes to the mixture as it proceeds through the system to 
promote the digestive process. In the small intestines, the final stages of chemical 
digestion occur and the nutrient or drug material is absorbed. The large intestine is 
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responsible for the reabsorption of water and the preparation of waste products. Left over 
products and waste materials pass from the large intestine and are stored in the terminal 
portion of the large intestine and the rectum until they pass out of the body through the 
anus.   
 Neuronal control is the first level controlling gastric function (Lingappa, 2000; 
Wingate & Phillips, 1998; Wood, 1998). Only the initial entry of the materials into the 
system (swallowing) and exit (defecation) are consciously controlled. Sensory input from 
seeing, smelling, or tasting foods invokes the central nervous system (CNS) to begin the 
processes required for ingesting and digesting what has been consumed. Pressure or a 
sensation of “fullness” in the rectum signals the need to evacuate this portion of the GI 
system. The CNS modulates constant motor activity in the GI system, with an increase in 
function noted in response to various inputs and feedback mechanisms. 
Control or awareness of many bodily activities is beyond human perception.  The 
autonomic nervous system (ANS) monitors these functions and regulates activities to 
maintain homeostasis. The ANS serves as a conduit for carrying information between the 
brain and the gut (Kellow, et al., 1999; Rees & Brown, 1998; Wingate & Phillips, 1998; 
Wood, 1998). It is divided into the parasympathetic and the sympathetic systems. The 
vagus and pelvic nerves supply the parasympathetic nervous system (PNS). These nerves 
receive and relay information directly from the target organs to the brain on muscle 
movement and GI system content.  The sympathetic nervous system (SNS) is supplied by 
the spinal cord and provides a route for transmission of noxious stimuli from the organs 
and tissues of the GI system to the brain. 
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 The GI system has its own center of control. The enteric nervous system (ENS) 
acts as an independent, integrated system that provides local control of gut functions, as 
well as interconnections between the gut, brain, and spinal cord (Kellow et al., 1999; 
Malagelada & Camilleri, 1998; Rees & Brown, 1998; Wingate & Phillips, 1998; Wood, 
1998). The circuits of the enteric nervous system are grouped together to form distinct 
networks:  the myenteric and submucosal plexuses, and the prevertebral ganglia. The 
myenteric plexus spans the length of the GI tract, lying between the longitudinal and 
circular muscle layers. The network receives intrinsic and extrinsic innervation. It 
provides motor innervation to the muscle layers and secretory motor innervation to the 
mucosa, as well as providing innervation to the enteric ganglia of the gall bladder and 
pancreas and sympathetic ganglia. The submucosal plexus is comprised of overlapping 
small and large ganglia found between the circular and mucosal layers of the intestines. 
This plexus plays an important role in controlling electrolyte secretions. The prevertebral 
ganglia form structures that connect extrinsic nerve fibers between the gut and spinal 
cord. This relay system allows for the passing of information between the GI system, 
spinal cord, and the brain. The enteric nervous system provides direct control of 
gastrointestinal function through its integrative design, while maintaining a modulatory 
communication pathway with the central nervous system.   
Electrical control is the second level responsible for gastric function. Motor or 
contractile activity modulated by gastric electrical activity is what actually produces the 
peristaltic movement through the GI tract (Camilleri & Prather, 1998; Falk, 1992; 
Quigley, 1996; Wingate & Phillips, 1998). Movement of nutrients through the GI tract is 
controlled by the programmed patterns of the enteric system. Gastrointestinal motor 
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function is managed through a set of commands controlling contractile activity and 
reflexes. A basic electrical rhythm is initiated in the body of the stomach (Kellow et al., 
1999; Malagelada & Camilleri, 1998; Quigley, 1996; Wingate & Phillips, 1998). This 
activity propagates toward the pylorus at a rate of three cycles per minute (Familoni, 
1994; Mintchev & Bowes, 1994; Rees & Brown, 1998). These slow waves form the basis 
for contractile activity in the stomach. Actual contractions do not occur with each cycle, 
but are based upon the imposition of an action potential on the plateau of the slow wave.  
During a fasting state, activity of the stomach is characterized by a pattern of cyclic 
electromechanical activity known as the migrating motor complex (MMC). This pattern 
of activity begins in the stomach and passes down the length of the small intestines about 
every ninety to one hundred twenty minutes. It has four phases. Phase I is characterized 
by regular slow waves without superimposed action potentials. This phase produces no 
motor activity. In phase II, slow waves are accompanied by intermittent action potentials 
resulting in irregular motor activity. During phase III, action potentials occur with each 
slow wave, producing regular, rhythmic contractions. Phase IV is the short transition 
period between constant activity and the return to phase I. Upon ingestion of a meal, the 
stomach immediately shifts into a fed state of motor activity. This state is characterized 
by irregular contractile activity in the stomach that last for a variable period, depending 
upon the type and volume of meal taken in (Falk, 1992; Quigley, 1996; Rees & Brown, 
1998; Wingate & Phillips, 1998).  
Chemical or hormonal mechanisms make up the third level of control in gastric 
function. An excitatory effect on gastric function is controlled using acetylcholine (Ach) 
as a transmitter. Inhibition of gastric function is accomplished using norepinephrine as a 
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transmitter. Hormones such as gastrin, cholecystokinin, secretin, motilin, glucagon, and 
vasoactive intestinal polypeptide, along with many others, are secreted in response to the 
type of nutrient consumed in an effort to control the rate of digestion (Camilleri & 
Prather, 1998; Rees & Brown, 1998; Lingappa, 2000; Malagelada & Camilleri, 1998).  
Gastric function is increased or is slowed down based upon feedback within the GI 
system. 
Control and coordination of GI function requires multiple pathways. Alterations 
and abnormalities in GI motor activities are linked to GI dysfunction.  The cause of the 
abnormality may stem from neurological, electrical, or chemical changes in the GI 
system. The effects of the alteration or abnormality may be manifest as unpleasant signs 
and symptoms such as nausea, vomiting, anorexia, bloating, constipation, or diarrhea, or 
may contribute to other problems associated with other disease and conditions affected by 
the stomach emptying too fast or too slow (Malagelada & Camilleri, 1998; Redel & 
Zwiener, 1998; Wingate & Phillips, 1998). 
 
Gastric Complications in Patients with Diabetes 
 The first description of dyspeptic symptoms associated with diabetes occurred 
over fifty years ago (Kassander, 1958; Rundles, 1945). Since then, studies have 
documented various findings related to the pathophysiology, diagnosis, and treatment of 
gastric dysfunction in patients with diabetes. Digestion and absorption of nutrients and 
drugs is important in controlling blood glucose levels and thereby preventing 
complications. Alterations in blood glucose levels affect the nervous system resulting in 
changes in the digestive system (Fischer, Heidemann, Hengst, Domschke, & Konturek, 
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1998). Changes in the digestive system contribute to problems with maintaining 
metabolic control, creating a cyclic pattern that contributes to further complications (El-
Salhy & Sitohy, 2001; Enck & Frieling, 1997; Jebbink et al., 1994). 
Changes in the normal digestive pattern occur in 30% to 50% of patients with 
diabetes (Annese et al., 1999; Enck & Frieling, 1997; Horowitz & Fraser, 1994, 1995; 
Horowitz, Wishart, Jones, & Hebbard, 1996; Koch, 1999; Rothstein, 1999). Alterations in 
the normal digestive pattern cause a potential mismatch in circulating insulin and nutrient 
availability, which increases the number of hyper and hypoglycemic events (Berne, 1996; 
Enck & Frieling, 1997; Horowitz & Fraser, 1994; Horowitz et al., 1996; Koch, 1999). 
Signs and symptoms reflecting alterations in normally coordinated movement of nutrients 
through the gastrointestinal tract such as nausea, vomiting, abdominal pain, anorexia, 
early satiety, or bloating usually occur in those patients experiencing alterations in 
digestion (Annese et al., 1999; Enck & Frieling, 1997; Horowitz & Fraser, 1994, 1995; 
Horowitz et al., 1996; Koch, 1999; Keshavarzian, Iber, & Vaeth, 1987; Kong, 
Macdonald, & Tattersall, 1996; Rothstein, 1999). Gastric stasis or retention is another 
consequence of an altered digestive pattern that causes problems in patients with diabetes 
(Annese et al., 1999; Enck & Frieling, 1997; Horowitz & Fraser, 1994, 1995; Horowitz et 
al., 1996; Koch, 1999; Rothstein, 1999). In published reports, 20% to 76% of patients 
with diabetes complain of upper gastrointestinal symptoms (Annese et al., 1999; Berne, 
1996; Enck & Frieling, 1997; Horowitz & Fraser, 1994, 1995; Horowitz et al, 1996; 
Koch, 1999; Kong et al., 1996; Keshavarzian et al., 1987; Rothstein, 1999). An actual 
determination of the incidence and prevalence of gastric symptoms has not been obtained 
since symptom occurrence may be intermittent (Barkin et al., 1997; Enck & Frieling, 
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1997) and since only symptomatic patents are usually evaluated (Kong et al., 1996). 
Correlational studies examining the relationship between gastric function and gastric 
symptoms have yielded inconsistent findings, moreover, not all patients will relate or 
report clinical symptoms (Barbar, Steffen, Wyllie, & Goske, 2000; Chen, Lin, Pan, & 
McCallum, 1996; Geldof, Van de Shee, Van Blankenstein, & Grashuis, 1986; Parkman et 
al., 1997; Pfaffenbach et al., 1998; Pfaffenbach et al., 1995; Rezende-Filho, 1995; 
Soykan, Lin, Sarosiek, & McCallum, 1999).  
 
Gastric Myoelectrical Activity and Electrogastrography 
The ability of the stomach to perform its normal propulsive activity is 
accomplished through GMA (Smout, Van de Shee, & Grashuis, 1980), which can be 
disrupted in patients with diabetes (Annese et al., 1999; Horowitz & Fraser, 1994; 
Rothstein, 1999). This cyclic motor activity occurs in a propagating fashion, propelling 
materials through the digestive system (Camilleri & Prather, 1998; Davenport, 1982; 
Koch & Stern, 1996; Phillips & Wingate, 1998). Gastric myoelectrical activity can be 
measured non-invasively, using EGG, in either a laboratory setting or as an ambulatory 
exam (Bellahsene et al., 1987; Camilleri et al., 1998; Familoni, Bowes, Kingma, & Cote, 
1991; Geldof et al., 1986; Koch, 1999; Mintchev, 2000). The cutaneous measurement of 
myoelectrical activity is accomplished by placing electrodes over the axis of the stomach, 
which allows for capturing electrical activity of the upper GI tract. The electrical activity 
of the stomach, much like that of the heart, follows a rhythmic, oscillating pattern. The 
tracings obtained record the pattern of GMA in both the fasting and post-prandial states, 
providing information about the gastric electrical control activity baseline frequency 
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(slow waves), electrical response activity (spikes) and rhythm (bradygastria, tachygastria, 
or dysrhythmias) (Bellahsene et al., 1987; Camilleri et al., 1998; Familoni et al., 1991; 
Koch, 2001; Maughan & Leiper, 1996; Mintchev, 2000; Smout et al., 1980). Cycles have 
been determined to range between 2 and 4 cycles per minute (cpm), with the established 
norm from 2.7 to 3.2 cpm (Bellahsene et al., 1987; Familoni, 1994; Familoni et al., 1991; 
Koch, 2001; Mintchev, 2000; Pfaffenbach et al., 1995; Rezende-Filho, 1995). No 
standard testing procedure for EGG has been established.  The test usually includes 
recording in both fasting and fed states for varying time frames. Levanon and Zhang 
(1998) found that a recording length of less than 30 minutes reduced the reliability and 
predictability of the results and therefore recommended a recording length of 30-60 
minutes in each state. A trained technician and a computer are required to perform and 
analyze the EGG. The procedure is easy to perform and requires minimal time to acquire 
data.  Electrogastrography can be easily repeated, does not involve expensive 
radiographic equipment, pain, or discomfort to the patient, making it an efficient clinical 
choice for assessing gastric motor activity. 
Electrogastrography has been used in multiple studies to assess gastric 
dysrhythmias and their relationship to gastric symptoms in diabetic patients. In the study 
of patients with type 1 diabetes, Koch, Stern, Stewart, and Vasey (1989) sought to obtain 
measures of GMA in diabetic patients with severe nausea and vomiting using EGG, and 
to determine the effect of long-term drug therapy on upper GI symptoms and EGG. The 
study evaluated six patients with nausea and vomiting. The patients were three men and 
three women, between the ages 22 to 65 years. Duration of diabetes ranged from seven to 
25 years. The participants reported upper GI symptoms from 3 months to 7 years in 
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duration, and were symptomatic at the time of the study. Electrogastrography was 
performed at baseline and after 6 months of prokinetic therapy. Following an 8-hour fast, 
EGG was recorded for 30 minutes. At baseline, EGG revealed gastric dysrhythmias. 
Tachygastria was noted in one patient, bradygastria in two patients, and a flatline pattern 
in three patients. The normal 3 cpm pattern was absent in all study participants. Mean 
upper GI symptom score was 17.8 ± 5 (range 9 – 27), with nausea, vomiting, distention, 
or early satiety rated severe by each patient. After 6 months of medication therapy with 
domperidone, normal 3 cpm frequencies were recorded from each of the six patients. The 
mean GI symptoms scores decreased significantly (3.7 ± 2.9, p < 0.01). These findings 
support the theory that gastric dysrhythmias and gastric symptoms are 
electrophysiological abnormalities, which can be assessed using EGG and that 
normalization of dysrhythmias contribute to symptom improvement.  
Soykan, Lin, Sarosiek, and McCallum (1999) studied EGG changes in diabetic 
patients and investigated the correlation between upper GI symptoms, fasting blood 
glucose, and gastric myoelectrical abnormalities. Fourteen patients with longstanding 
type 1 diabetes were assessed using 30-minute fasting and 2-hour post-prandial EGG 
recordings. Symptoms of nausea, vomiting, early satiety, bloating, and pain were rated on 
a scale from zero to three, with higher scores indicating more severe symptoms. Mean 
symptom scores were significantly higher in patients with abnormal EGG than patients 
with normal EGGs (2.42 ± 0.13 cpm vs. 2.0 ± 0.16 cpm, p < 0.05). There was no 
significant differences in fasting glucose levels in abnormal EGG patients (288 ± 86.4 
mg/dl) compared to normal EGG patients (304 ± 57.6 mg/dl, p = 0.214), with both 
groups being hyperglycemic. Seven out of fourteen patients (50%) studied had abnormal 
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EGG findings. Two had dysrhythmic preprandial EGGs and all had decreased post-
prandial EGG power. Two had normal preprandial EGGs but decreased post-prandial 
EGG power. The authors concluded that EGG could be an important screening tool for 
evaluating abnormal gastric motility in symptomatic diabetic patients. 
In studies aimed at detecting prominence of abnormal EGG frequency, 
Mayaudon, et al. (1999) studied 54 type 1 diabetic patients (13 male, 41 female; mean 
age 43 years) and 15 healthy age and sex matched non-diabetic controls. Diabetic patients 
were asymptomatic. Electrogastrography was recorded for 4 hours before, during, and 4 
hours after the ingestion of a standard meal.  The authors found that tachygastria (EGG > 
4 cpm) was significantly more common in type 1 diabetic patients than in controls. 
Patients experienced more tachygastria than controls throughout the recording period 
(38% ± 5 vs. 23% ± 11.8, p < 0.001), as well as before (37% ± 6 vs. 26.5% ± 8.9, p < 
0.001), during (41% ± 7.8 vs. 23% ± 10.5, p < 0.001), and after the meal (37% ± 6.9 vs. 
29% ± 9.8, p < 0.001). The percentage of dominant frequency in the normal range was 
significantly lower in patients with diabetes than in controls (49% ± 6 vs. 63.3% ± 11.1, p 
< 0.001). The authors concluded that EGG could be used for the detection of gastric 
dysrhythmias in asymptomatic diabetic patients.   
Mantides et al. (1997) also assessed GMA in asymptomatic patients with type 1 
diabetes. A group of 10 type 1 patients (6 men, 4 women, mean age 59.9 ± 6.1 years) was 
compared to 9 healthy controls (5 men, 4 women, mean age 49.5 ± 14.8 years). 
Electrogastrography with a 2-hour fasting/post-prandial recording, frequency and fed/fast 
ratio of slow wave power was assessed. The study found gastric myoelectrical 
abnormalities, with bradygastria being the predominate frequency (46.8 ± 16.2% time). 
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Normogastria was present 35.1 ± 13.2% of the time and tachygastria was noted 17.2 ± 
10.2% of the time. Additionally, normogastria did not increase significantly after the 
meal in patients with diabetes as it did in controls. The fed/fasting ratio of the EGG 
power was 1.13 ± 0.25 for bradygastria, 1.67 ± 0.33 for normogastria, and 0.78 ± 0.35 for 
tachygastria. Slow wave power decreased post-prandially in diabetic patients with 
bradygastria (0.82 ± 0.23, p = 0.006) and normogastria (0.73 ± 0.32, p < 0.0001), but not 
with tachygastria where an increase in EGG power was observed (3.47 ± 1.55, p = 
0.0002). The authors concluded that gastric dysrhythmias exist without upper GI 
symptoms and that bradygastria and failure to increase slow-wave amplitude post-
prandially are the predominant forms of abnormal myoelectrical activity in adults with 
type 1 diabetes.  
Kawagishi et al. (1997) studied GMA in 10 type 1 and 47 type 2 patients with 
diabetes and 10 healthy control subjects using EGG to elucidate the relationship between 
glucose control, diabetic autonomic neuropathy, and gastrointestinal motility. Cutaneous 
EGG was recorded for 1 hour fasting and 1 hour post-prandially in all subjects. The 
participants were questioned regarding GI symptoms using a standard questionnaire and a 
3-point rating scale. Autonomic neuropathy was assessed using standard cardiovascular 
reflex test. Electrogastrography and autonomic function test were repeated in 12 diabetic 
patients after glycemic control for 4 weeks. Autonomic neuropathy was identified in 33 
of the 57 patients. Eight of the patients had borderline autonomic neuropathy, and 16 had 
normal autonomic nerve function. The two diabetic groups had similar fasting plasma 
glucose levels and hemoglobin A1c (HbA1c) concentrations. Normogastria was 
significantly lower in diabetic patients with autonomic neuropathy (37 ± 4%) than in 
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control subjects (66.7 ± 5.2%, p < 0.01). The relationship between the percentage of time 
in normogastria and HbA1c concentrations was non-significant in diabetic patients (r = -
0.206, p = 0.123). The dominant frequency instability coefficient (DFIC) was 
significantly high in diabetic patients with (42.4 ± 2.5%) and without autonomic 
neuropathy (40.8 ± 3.1%) as compared to control subjects (26.2 ± 1.8%, p = 0.01). The 
DFIC was correlated significantly with HbA1c concentrations in diabetic patients (r = 
0.315, p = 0.017). The post-prandial-to-fasting power ratio (PR) was significantly lower 
in diabetic patients with autonomic neuropathy (1.2 ± 0.1) compared with control 
subjects (3.1 ± 0.7) or with diabetic patients without autonomic neuropathy (2.1 ± 0.2, p 
= 0.01). No significant relationship between the PR and HbA1c concentration was found 
in diabetic patients. Gastrointestinal symptom scores were significantly higher in patients 
with autonomic neuropathy as compared to those without autonomic neuropathy.  Of the 
57 diabetic patients, 27 had GI symptoms. These scores did not, however, correlate with 
any parameter of GMA during the study. After 4 weeks of glycemic control, the DFIC 
and the percentage of time in normogastria improved significantly when compared with 
the baseline period (p = 0.0096; p = 0.0409, respectively), but the PR did not change 
significantly (p = 0.05). The investigators in this study observed a decrease in the PR and 
percentage of time in normogastria and an increase in the DFIC in patients with 
autonomic neuropathy in the absence of glycemic control. They concluded that both 
glucose control and autonomic nerve function are important factors in regulating GMA, 
and that changes in GMA are partly reversible with glucose control. 
Gad-el-Hak and Bakr (2001) investigated patterns of GMA in type 2 diabetic 
patients detected by EGG. The study included 34 subjects (7 male, 27 female, mean age 
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51.5 ± 3.5 years). Using a 30-minute fasting and 30- minute post-prandial ambulatory 
recording, EGG abnormalities were found in 13 patients (38.2%). One subject had 
tachygastria, 1 had bradygastria, and 7 had mixed dysrhythmias (periods of bradygastria 
and tachygastria). Four subjects had decreased post-prandial power. The authors 
concluded that gastric myoelectrical abnormalities occur in a high proportion of type 2 
diabetic patients.  
Similarly, Mathur, et al., (2001) assessed the rate of gastric dysrhythmias and 
post-prandial EGG changes in patients with type 2 diabetes. Seventy-one subjects (44 
male, 27 female, mean age 62 ± 11.9 years) were studied. Analyzing a 1-hour fasting and 
2-hour post-prandial EGG recording, 85% (60/71) of the patients had abnormalities in the 
fasting state. The amount of time spent in tachygastria and bradygastria during the fasting 
state was 21 ± 13.6% and 26.1 ± 21.7%, respectively. The amount of time in normal 
gastric rhythm was 44.7 ± 20.2% while fasting. Eighty-three percent (59/71) of the 
subjects had gastric rhythm abnormalities in the post-prandial period. The percent 
tachygastria and bradygastria during the post-prandial state was 24.5 ± 16.3% and 21.1 ± 
19.2%, respectively. The amount of time in normal rhythm post-prandially was 48.5 ± 
19.9%. Sixty-five percent (46/71) of subjects improved their EGG recordings in response 
to a test meal; 35% (25/71) did not respond. Fasting bradygastria was associated with 
responders, while fasting tachygastria was associated with non-responders. There was no 
correlation between abnormal EGG rhythms and glucose levels or gastric symptoms. The 
authors concluded that gastric rhythm disturbances were common in patients with type 2 
diabetes and that abnormal gastric rhythms may be predictive of delayed gastric 
emptying.  
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A 2002 study by Qi, Luo, and Wang had findings similar to those in previous 
studies. This study investigated GMA and its relationship in diabetic patients with upper 
GI symptoms using EGG. The study valuated 32 symptomatic type 2 patients (17 male, 
15 female, mean age 51 years) and 22 healthy controls (11 male, 11 female, mean age 50 
years). A 30-minute fasting EGG recording followed by a 30-minute post-prandial 
recording was used. Patients had a lower instance of normal EGG than controls in both 
the fasting and the fed states (38% vs. 96%, p < 0.01, 34% vs. 86%, p < 0.01, 
respectively). Patients also had a higher incidence of abnormal EGG (tachygastria and 
bradygastria) than controls in both the fasting and fed states (63% vs. 5%, p < 0.01, 66% 
vs. 14%, p < 0.01, respectively). The mean post-prandial dominant frequency was lower 
for patients (2.61 ± 0.29, p < 0.05) than for controls (3.76 ± 0.14, p < 0.05), as was the 
post-prandial/preprandial dominant frequency ratio (1.01 ± 0.10, p < 0.05 for patients 
versus 1.28 ± 0.11, p < 0.05 for controls). Of the 32 diabetic patients with upper GI 
symptoms, 21 (66%) had abnormal EGG. The study supported findings from previous 
studies, which showed that diabetic patients with upper GI symptoms have GMA that can 
be assessed using EGG. Results of this study further the knowledge of the complexity of 
the components of GMA and its importance in normal gastric function. 
Electrogastrography in this and previous studies continues to be a useful tool in detecting 
and assessing changes in GMA. 
Controversial studies also exist in the study of GMA in patients with diabetes. 
Some studies have not found EGG to be a useful tool in determining differences between 
patients with diabetes and normal controls. Pfaffenbach, et al (1995) investigated whether 
EGG could really predict a gastric motility disorder in type 2 diabetic patients with 
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chronic symptoms. Eighteen patients with type 2 diabetes (9 male, 9 female, median age 
64) and 20 age and gender matched healthy controls (10 male, 10 female, median age 68 
years) were studied. Following an overnight fast, EGG values were obtained during a 1-
hour fasting and 1-hour fed state. The presence of GI symptoms was assessed 
immediately before the measurements. The authors found no significant differences 
among any of the EGG variables between the subjects and controls. Both groups showed 
predominantly normal frequencies. Bradygastria and tachygastria were significantly less 
common in both the pre-prandial and post-prandial period in subjects and controls (p < 
0.05). There was no significant correlation between EGG and any of the clinical variables 
studied, including gastric symptoms and blood glucose. This study concluded that EGG 
was not a reliable tool for assessing gastric motility.  
Jebbink, et al. (1994) examined the prevalence of gastric myoelectrical 
abnormalities and their relationship to upper GI symptoms in patients with type 1 
diabetes. The study was performed in 30 patients (19 male, 11 female, mean age 45.5 ± 
2.5 years) and 12 healthy sex, age, and weight matched controls (7 male, 5 female, mean 
age 46.3 ± 3.7 years). All participants were interviewed prior to beginning the study to 
determine the presence and severity of symptoms experienced the week before the study. 
Upper GI symptoms were also assessed before the start of the meal and at the end of the 
study. A meal symptom score was calculated from these scores. EGG recordings were 
obtained for 2-hours fasting and 3-hours after a standard meal. The incidence of 
dysrhythmias, such as tachygastria and bradygastria, was not higher in patients than in 
controls (17% and 8%, respectively). There were no differences between patients and 
controls in mean EGG frequencies in either the fasting or post-prandial state (0.0489 ± 
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0.0006 vs. 0.0478 ± 0.0001; 0.0488 ± 0.0006 vs. 0.0494 ± 0.0009, respectively). No 
differences were found between other EGG parameters between patients with and 
without symptoms during the study. The authors concluded that patients with type 1 
diabetes studied under euglycemic conditions did not have grossly disturbed gastric 
myoelectrical activity except when symptomatic during the study. 
El-Salhy and Sitohy (2001) studied GMA in patients (n = 12, 9 women and 3 
men; mean age 45 years) with type 1 diabetes and in controls (n = 38, 26 women and 12 
men; mean age 37 years). No statistically significant differences were found in dominant 
frequencies in either the fasting (controls 3 ± 0.03 cpm vs. patients 2.9 ± 0.09 cpm) or the 
post-prandial state (controls 3 ± 0.05 cpm vs. patients 3 ± 0.09 cpm). While this study 
was able to assess GMA, no differences could be found between subjects and healthy 
controls. 
 
Summary 
In this review, specific literature related to the pathophysiology of diabetes 
mellitus, gastric complications in patients with diabetes, and GMA in patients with 
diabetes has been presented. Evidence of similarities and differences between type 1 and 
type 2 diabetes are emphasized. Controversial results are also presented. Given the 
information available at this time, the use of EGG in patients with diabetes as a clinical 
tool remains questionable. Further research is needed to definitively support the use of 
this technology in this and other patient groups. While EGG consistently detected 
patterns of altered GMA in these studies, any conclusions drawn about the relationships 
between GMA, GI symptoms, and metabolic control are viewed tentatively as the studies 
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were conducted in small numbers of patients under different conditions. Additional work 
with a larger sample of symptomatic and asymptomatic participants within a consistent 
setting would assist in drawing more valid conclusions. The present study will contribute 
to the pool of knowledge related to GMA, GI signs and symptoms, and level of metabolic 
control in persons diagnosed with diabetes mellitus by further assessing and/or validating 
the links between these relationships in a single, controlled study.  
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CHAPTER 3.  METHODOLOGY 
 
Introduction 
The hallmark manifestation of diabetes mellitus is an uncontrolled blood glucose 
level. Hyperglycemic effects are linked to the development of diabetes complications, 
including the development of autonomic nervous system dysfunction (ADA, 2003; 
Davidson, 1998; DRWG, 1999; Krall & Beaser, 1989; NIDDK, 2003). Alterations in 
gastric function occur because of changes in autonomic function and hormonal 
regulation. These changes are associated with the development of both upper GI 
symptoms and hyper- and hypoglycemic events (Camilleri & Prater, 1998; Creyer, 1998; 
Davenport, 1982; Horowitz, Wishart, Jones, & Hebbard, 1996; Koch, 1999; Koch & 
Stern, 1996; Muggeo, 1998; Phillips & Wingate, 1998). Upper GI symptoms and 
difficulty maintaining metabolic control are among the complaints of patients with 
diabetes mellitus (Annese, et. al., 1999; Berne, 1996; Enck & Frieling, 1997; Horowitz & 
Fraser, 1994, 1995; Horowitz, Wishart, Jones, & Hebbard, 1996; Koch, 1999; Kong, 
Macdonald, & Tattersall, 1996; Rothstein, 1999).   
Not all patients experience upper GI symptoms, but for those who do, the 
presence of nausea, vomiting, abdominal pain, bloating, and early satiety, is usually 
unpleasant, and often complicates their self-care practices, adherence to treatment, and 
ultimately, QOL (Siddique, Ricci, Stewart, Sloan, & Farup, 2002; Talley, et al., 2001). 
Changes in the normal digestive pattern contribute to problems with maintaining 
metabolic control, as there is a mismatch in circulating insulin and nutrient availability 
(Creyer, 1998; Horowitz, Wishart, Jones, & Hebbard, 1996; Koch, 1999; Muggeo, 1998). 
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The GI system maintains the digestive pattern through contractile and propulsive activity 
that is driven by GMA. This activity is disrupted because of diabetic neuropathy 
(Camilleri & Prater, 1998; Koch & Stern, 1996; Phillips & Wingate, 1998).  
Electrogastrography allows for the cutaneous measurement of GMA (Familoni, 
Bowes, Kingma, & Cote, 1991; Mintchev, 2000; Palmieri, Schulze-Delrieu, & Raab, 
1992; Parkman et al., 1997; Pfaffenbach et al., 1998; Rezende-Filho, 1995). Researchers 
using EGG have demonstrated the ability to distinguish patterns of GMA in healthy 
subjects from patterns observed in the presence of disease (Geldof et al., 1986; 
Pfaffenbach et al, 1995). This instrument is easy to use, costs less, and is less time 
consuming than other tests of gastric function, and is well tolerated by patients. Assessing 
GMA in patients with diabetes could prove valuable. Identification of specific patterns of 
GMA that correlate with specific symptoms and/or levels of metabolic control could be 
used to assess treatment associated improvements in this population once interventions 
have been developed to address these problems. While patterns of GMA observed in 
study patients will be categorized as normogastria, bradygastria, and tachygastria using 
established cut-points documented in the literature, EGG results reported in this study do 
not reflect a medical diagnosis. Traditionally suspected gastric dysfunction identified 
through EGG assessment is confirmed using more sensitive and specific tests.  
The purposes of this pilot study were to assess and describe GMA in patients with 
diabetes mellitus using EGG. Additionally, the study sought to determine if specific 
patterns of GMA correspond with levels of symptom presence and severity, glucose 
control, age, or length of diagnosis in patients with diabetes. This chapter presents the 
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research design, setting and sample, recruitment, instrumentation, and procedures used in 
this investigation. 
 
Research Design 
A descriptive, correlation design was used to depict the associations among 
gastric myoelectrical activity, upper GI symptoms, and glucose control, and to determine 
whether upper GI signs and symptoms, glucose control, age, or length of diagnosis could 
be correlated with the pattern of GMA identified using EGG. Measurements of GMA, 
upper GI signs and symptoms, and glucose control were obtained. Demographic 
information including age, gender, length of diabetes, diet history, and medications taken, 
were obtained during patient interview as these factors could influence gastric function or 
upper GI symptoms. The Institutional Review Board (IRB) of the University of 
Tennessee Health Science Center granted approval for the study (see Appendix A for the 
IRB approval).  
 
Setting 
Data were collected at the Center for Health Evaluation and Lifestyle Promotion 
(HELP Center), which is located on the University of Tennessee Health Science Center 
(UTHSC) campus in Memphis, Tennessee. The HELP Center is located on the fifth floor 
of the Professional Building. This center serves as a primary care center, research 
laboratory, and site for various studies. A designated interview and exam room was setup 
to accommodate this study, including an area for phlebotomy, completion of 
demographic information, study questionnaires, and EGG testing.  
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Sample 
The total non-probability convenience sample consisted of  25 individuals, 5 
subjects diagnosed with type 1 diabetes mellitus, 13 subjects diagnosed with type 2 
diabetes mellitus, and 7 healthy controls. The sample was comprised of 17 women and 8 
men. Nineteen of the participants were African American, 6 were Caucasian. The 
following inclusion and exclusion criteria were used to select study participants: 
1.  General Inclusion Criteria for Subjects and Controls 
a. Persons 12 years of age or older; 
b. Could read, write, and speak English; 
c. Agreed to be in the study. 
2. Inclusion Criteria for Subjects Included 
a. Diagnosis of type 1 or type 2 diabetes mellitus; 
b. Fulfilled general inclusion criteria. 
3. Exclusion Criteria for Subjects and Controls 
a. Persons less than 12 years of age; 
b. Have a history of gastrointestinal disease or conditions (peptic ulcer disease 
(PUD), gastroesophageal reflux disease (GERD), pancreatitis, uremia, 
Crohn’s disease, ulcerative colitis (UC), irritable bowel disease (IBD), lactose 
intolerance, or eating disorders (Anorexia, Bulimia);  
c. Currently being treated with medications known to affect gastrointestinal 
motility (Reglan, Cisapride, Domperidone, Erythromycin), gastric acid 
suppressants (Zantac, Tagamet, Prilosec, Pepcid, Axid, Prevacid, Nexium), or 
antiemetics (Phenergan, Compazine, Inapsine, Benedryl, Zofran, Kytril) who 
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are unable or unwilling to be off the medication for at least 72 hours prior to 
testing; 
d. Pregnancy.  
Of the 37 persons originally expressing interest in participating in the study, 27 
ultimately participated (72.3% participation rate). Six subjects repeatedly missed 
scheduled appointments, and four did not wish to undergo blood sampling. Of the 10 
potential participants, 6 were female and 4 were male. Four of the women were 
diagnosed with type 2 diabetes; 5 were Caucasian. Three of the male subjects were type 1 
diabetics; two were Caucasian. The mean age of this group was 25.6 years (range 16 – 
32). Data from 2 participants were lost due to compact disc corruption, making them 
unreadable. One participant was a 15 year old type 1 African-American female; the 
second was a 75 year old African-American female serving as a control. 
 
Recruitment 
The participants for this study were recruited through university-associated 
physicians and nurse practitioners, or from flyers strategically posted in well-traveled 
locations on the UTHSC Campus and University of Tennessee Bowld (UTB) Hospital.  
Endocrinologist in practice at local offices agreed to allow participant recruitment during 
normal clinic hours. These clinics primarily focused on the management of patients with 
type 1 and type 2 diabetes and hyperlipidemia. After identification of a potential 
participant, the physician was consulted or the candidate’s medical record was reviewed 
(with permission of the patient) to determine if eligibility requirements were met. Those 
candidates meeting inclusion/exclusion criteria were asked if they would be interested in 
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participating in the research study. Callers indicating an interest in participating as a 
patient or normal control in the study were provided with an explanation of the purpose 
and requirements for the study. Respondents indicating a continued interest in 
participating in the study and meeting the inclusion/exclusion criteria were scheduled to 
come into the HELP Center. After a review of the person’s medical history, written 
informed consent (see Appendix B) was obtained and the testing procedures completed as 
described in the study procedure. Data were collected between October 2002 and March 
2004. 
 
Instrumentation 
 All data were obtained by the principal investigator and entered immediately into 
a password protected computerized database. The participant’s name, current age, gender, 
race, marital status, occupation, years of education, and employment status was recorded 
for demographic consideration. Health history information including height, weight, 
current medications and illnesses, smoking history, years of diabetes, age at diabetes 
onset, and for females a menstrual history, was obtained. Address, phone number, and 
social security number were recorded in a separate password protected database file for 
re-contact purposes (see Appendix C). Anonymity was ensured after completion of the 
paper form by replacing the participant’s name with a unique identification number 
generated and cross-referenced by the database entry. The data were backed up to a read-
only CD-ROM after each data entry session occurred. Backup discs were secured in a 
locked file only accessible by the principal investigator and collaborating investigators.  
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Procedures 
All participants underwent the same procedure (see Appendix D). Following an 
overnight fast, the subject was directed to report to the HELP Center. Other directions 
included taking all regular medications as prescribed (except GI meds excluded 
previously), and wearing comfortable clothing that would allow for exposure of the 
abdomen. At the scheduled appointment time in the HELP Center, informed consent was 
obtained and a review of medical history was undertaken. Demographic data and blood 
samples were taken in a designated intake room. In the event the subject was found to be 
hyperglycemic, treatment according to the plan established by the regular physician or 
practitioner was implemented.  This included administering sliding scale insulin by 
injection or pump bolus. The participant was encouraged to use the restroom, then 
directed to a room designated for collection of EGG data. 
 
Measurement of Metabolic Control 
Blood samples were obtained to determine the current level of metabolic control, 
and to establish a baseline by which one could identify acute changes in blood glucose 
levels. Approximately 10 milliliters (2 teaspoonfuls) of blood were drawn via peripheral 
venipuncture by an experienced laboratory technician for the measurement of 
glycosolated hemoglobin (GHB). Glycosolated hemoglobin measures the overall blood 
glucose control for the past 2 to 3 months (Labcorp, 2001). As the hemoglobin in red 
blood cells travels through the blood stream, it acquires a glucose coating or 
glycosylation. The higher the blood glucose, the more coating the cells acquire. The 
result of this test was reported as a GHB level (%). Reference GHB based upon 
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laboratory protocol is 4.2% to 7.0%. The glucose control index for near normal control is 
7.0% to 8.0%; the range indicating good control is 8.0% to 9.0%; and a GHB level 
greater than 9.0% is indication for action or intervention (Labcorp, 2001). 
The blood sampling occurred after reviewing and completing the informed 
consent, demographic form, and symptom questionnaires and prior to beginning EGG 
data collection. A non-latex tourniquet was applied above the antecubital area of the 
patient’s preferred arm. After identifying an appropriate vessel for venipuncture, the site 
was prepped with alcohol and allowed to dry.  A 22 gauge butterfly catheter with 
preattached tubing was used to puncture the vein and deliver the sample to a lavender 
vacutainer tube. The tube was labeled with the individual’s unique identifier; the 
appropriate lab requisition was then completed and the specimen taken within 30 minutes 
to the laboratory pick-up station. 
Fingerstick blood glucose testing was performed to assess acute changes in the 
circulating glucose in the blood during the EGG testing procedure. This method of testing 
was used to evaluate changes in the blood glucose levels post-prandially and provide data 
for assessing changes in patterns of GMA and symptoms as the blood glucose level 
changed. Recommended glycemic goals are 80-120 mg/dl preprandially and average 
bedtime glucose of 100-140 mg/dl (ADA, 2003). Testing was performed using a 
LifeScan One Touch Ultra monitoring device prior to beginning EGG data collection, 
immediately before serving the test meal, and at 30-minute intervals after eating the meal 
until the end of the testing procedure.  The investigator calibrated the device according to 
company procedure before each participant session.  
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To obtain the sample the participant was allowed to select the finger used to 
puncture. The finger was cleaned with alcohol and allowed to dry. Pressure was applied 
to the finger to “milk” blood into its tip. A lancet device was then used to puncture the 
fingertip. The first drop of blood was wiped away using a clean cotton ball. The next drop 
was applied to the testing strip. The monitor required 5 seconds to process the specimen; 
the results were displayed on the meter. The result was recorded on the patient’s data 
collection sheet at that time. 
 
Measurement of Upper Gastrointestinal Symptoms 
The presence and severity of acute upper GI signs and symptoms was assessed 
prior to beginning collection of EGG data, immediately before, and at 30 minute intervals 
after the test meal was consumed, until the end of the testing period, using a visual analog 
scale (VAS) (0-100 mm) to assess each symptom (see Appendix E). Visual analog scale 
reliability and validity has been tested and found to be a methodologically sound 
instrument for assessment of subjective phenomenon (Gallagher, Bijur, Latimer, & 
Silver, 2002; Gift, 1989; Luria, 1975).  
The participant was instructed to draw a single line horizontally across the vertical 
VAS line at the level relative to his or her symptom. A mark at the level of zero was used 
to indicate no nausea, vomiting, pain, bloating, or satiety. A mark at the level of 100 used 
to indicate the presence of severe symptoms. The 100 mm ruler used to initially draw the 
line for the VAS was placed next to the line and the mark made by the participant was 
numerically qualified. The number was recorded on the data collection sheet. An account 
of past GI symptoms (i.e. historical symptoms) was assessed using the Total Symptom 
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Score (TSS) (see Appendix F). The TSS, a 6-item questionnaire, was administered prior 
to the EGG to evaluate the presence and severity of GI symptoms and their overall 
impact on the patient’s general health over the past 2 months. This instrument has been 
found a reliable tool to detect the presence and severity of GI symptoms in multiple 
studies (Abell, Cutts, Cooper & 1993; Cutts, Abell, Karas, & Kuns, 1996; Hathaway et 
al., 1993).  
The participant was given the tool and instructions on how to complete it 
including answering the question related to the individual symptom “yes” or “no”. For an 
affirmative answer the participant was asked to circle the number corresponding to the 
intensity of the individual symptom over the past two months. The sixth question on the 
survey was a summary question for which the participant quantified the effects of the 
combined gastrointestinal symptoms on overall health. 
 
Measurement of Gastric Myoelectrical Activity 
Electrogastrography was used to evaluate GMA. After obtaining consent, 
collecting initial data and addressing the need to use the bathroom, the participant was 
taken to the room where the EGG was performed. This room was sound, climate, and 
light controlled to maximize relaxation. The subject was allowed to rest in a supine 
position in a reclining chair. The skin on the surface of the abdomen was cleaned with 
sterile rubbing alcohol and hair shaved, if necessary, to assure adequate electrode contact 
with the skin. Silver chloride electrodes placed on the abdomen were used to record the 
EGG using the standard placement arrangement used at the HELP Center (see Figure 2).  
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Figure 2. EEG Electrode Placement 
Note. EGG electrodes are attached to abdominal wall with a standard positive electrode 
over the antrum of the stomach on the mid-clavicular line just below the rib cage, a 
standard negative electrode is placed in a mirror image position on the right side of the 
abdomen at the mid-clavicular line. 
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After 30 minutes of data collection in the fasting state, the participant was served a 
standard meal consisting of 1 egg, 1 slice of whole wheat bread, and 8 ounces of skim 
milk (219 kcal, 35% protein, 52% carbohydrates, 13% fat, and 2 gm fiber). Data 
collection continued for another 1.5 hours to capture activity in the post-prandial or “fed” 
state.  Data from the fasting period, 30 minutes after the meal (first post-prandial period), 
and 120 minutes after the meal (fifth post-prandial period), were analyzed for the 
purposes of the present study. These time periods were selected based on previous 
recommendations and according to their frequency found in the literature. These time 
periods also allowed consistent with the time normally required for digestion to occur. 
Data were collected and analysis was performed on a dedicated personal 
computer using a Biopac MP-100 system and Acknowledge Software Version 3.71 
(Biopac, 2000). The MP 100 system is equipped with 16 analog channels with a 
input/output voltage range of ± 10V. It has a sampling rate of 70K samples/second. The 
EGG data were transferred to the personal computer via Ethernet interface.  
Electrogastrography frequency was determined for each patient by filtering at 
low/high band pass filter of .016 to 0.25Hz. This was used to remove any signal below 1 
cpm or above 15 cpm. A visual inspection of the tracing was completed. Segments noted 
to have artifacts were deleted. Fast Fourier Transformation (FFT) was completed using 
the Acknowledge™ software to obtain the dominant frequency, which translates into the 
number of cpms of the EGG signal. Example tracings are shown in Figure 3. 
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Figure 3. Examples of EGG Tracings 
 
Note.  Sixty-second increments of tracings were visually and electronically reviewed to 
determine EGG frequency.  The vertical bars indicate 60-second intervals. 
 
Normogastria 
Bradygastria 
 
Tachygastria 
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Data Analysis 
The primary investigator gathered all study data, making sure that all 
questionnaire items were addressed and answers properly recorded during each testing 
session. Data from questionnaires were coded for confidentiality and anonymity, then 
transferred to a Microsoft Excel spread sheet and stored on write-protected media. 
Electrogastrography data files were saved to computer disc at the time of collection. 
Patient characteristics such as gender, race, age, and other variables were summarized. 
Descriptive statistics were performed to characterize the sample. The statistical analysis 
for this study included Chi Square and Kruskal-Wallis testing procedures using SAS 
9.1.3. The level of significance was set at .05 for the research questions. Because of the 
small size obtained during this pilot study, more aggressive data analysis was not 
appropriate. Small groups were not excluded from the analysis as this would further 
reduce the sample size. 
Specific aims of this study were to 1) characterize the pattern of GMA in patients 
with diabetes, and 2) describe the relationships among patterns of GMA, symptom 
presence and severity, acute blood glucose level, long-term metabolic control, age, and 
length of diagnosis in patients with diabetes. The following two research questions and 
their associated questions were studied. 
 
Research Question 1 
The following were the questions associated with Question 1 (What patterns of 
GMA can be assessed using EGG in patients with diabetes?): 
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1a. What are the differences in patterns of GMA in healthy individuals versus 
diabetic patients?  
1b. What are the differences in patterns of GMA in patients with type 1 versus type 2 
diabetes? 
 To answer questions 1a and 1b, the mean frequency for EGG was determined and 
patterns of GMA for each period were obtained for the study participants. The values 
were categorized into bradygastria, tachygastria, or normogastria. Chi square test were 
utilized to evaluate the differences in frequencies between the normal and diseased 
groups and between groups diagnosed with type 1 and type 2 diabetes.   
 
Research Question 2 
The following were the questions associated with Question 2 (What is the 
relationship of patterns of GMA with upper GI symptoms, acute blood glucose 
measurement, metabolic control, age, and length of diagnosis in patients with diabetes 
mellitus?): 
2a. What is the relationship of patterns of GMA with upper GI symptoms, acute 
blood glucose measurement, metabolic control, age, and length of diagnosis in 
patients with diabetes mellitus who are fasting? 
2b. What is the relationship of patterns of GMA with upper GI symptoms, acute 
blood glucose measurement, metabolic control, age, and length of diagnosis in 
patients with diabetes mellitus who are 30 minutes post-prandial? 
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2c. What is the relationship of patterns of GMA with upper GI symptoms, acute 
blood glucose measurement, metabolic control, age, and length of diagnosis in 
patients with diabetes mellitus who are 120 minutes post-prandial?  
For research questions 2a, 2b, and 2c, the Kruskal-Wallis test was used to 
determine if significant relationships existed between variables. The patterns of GMA 
(bradygastria, normogastria, or tachygastria) were evaluated in relation to the 
participant’s recollection of the presence and severity of UGI signs and symptoms 
assessed using the TSS, the presence and severity of UGI signs and symptoms during the 
testing procedure using a VAS, acute blood glucose measurement, GHB, patient age at 
time of study, and length of diagnosis. 
 
Protection of Human Subjects 
 Minimal risks to participants in this study were identified and steps throughout the 
study to eliminate or reduce risk, maintain participant confidentiality, and assure privacy 
were included. Risks to the participant during this study included hypo- or hyperglycemia 
in response to fasting or meal consumption, an increase in gastric symptoms, and pain or 
hematoma from having multiple blood samples taken. The investigator performed blood 
glucose monitoring throughout the test, reported the results to the participant, and 
allowed treatment interventions based upon the participant’s usual protocol. Alternate site 
testing (forearm, hand) was available for those participants wishing to avoid fingersticks, 
although none chose to use them. These alternative sites have been validated by the 
monitor manufacturer and in previous studies (Coble, 2001; LifeScan, 2002). An 
 54
assessment of allergies and examination of the participant’s skin for signs of irritation 
was performed prior to securing EGG electrodes. Areas of skin irritation were avoided. 
 All identifying information was deleted or encrypted to avoid violating any of the 
participant’s legal or ethical rights. The need for the study was fully explained and the 
participant was given the opportunity to ask questions and received answers to their 
satisfaction prior to being asked to participate in the study. Assurance that the decision to 
participate or decline to participate in the study would not affect the care that was 
normally required or delivered was given. Informed, voluntary written consent was 
obtained prior to any data collection and a copy of the consent form provided to each 
subject. The Institutional Review Board (IRB) of UTHSC granted approval for the study. 
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CHAPTER 4.  RESULTS 
 
Introduction 
 The purposes of this pilot study were to assess and describe GMA in patients with 
diabetes using EGG, and determine if specific patterns of GMA corresponded with levels 
of symptom presence and severity, level of glucose control, age, or length of diagnosis 
during three periods: fasting, 30-minutes post prandial, and 120-minutes post-prandial. 
Identifying and understanding these relationships could assist the healthcare provider in 
planning strategies and treatments that reduce the burden and complications of diabetes. 
This chapter includes a description of the sample demographics, analysis of research 
questions, and related findings. 
 
Description of the Sample 
 All participants meeting inclusion criteria were enrolled. Table 1 summarizes the 
sample’s characteristics.  A total of 25 persons participated, including 17 women (68%) 
and 8 men (32%).  The participants ranged in age from 15 to 74 years, with a mean age of 
45.5 (SD = 14.1) years. Nineteen (76%) of the participants were African American, six 
(24%) were Caucasian. The mean fasting blood glucose measurement for the sample was 
165 mg/dl. Fasting blood glucose levels ranged from 71 mg/dl to 379 mg/dl (SD = 
83mg/dl). The mean GHB was 8.24% (range = 4.9 – 13.3%; mode 5.7%). Upper GI 
symptoms were mildly problematic for the sample with a mean total symptom summary 
score of 3.48 (SD = 2.74). The mean fasting EGG frequency for the sample was 2.53 cpm  
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Table 1. Descriptive Statistics for Study Participants by Controls and Patients with Type 1 and Type 2 Diabetes 
 
 
       Controls         Type 1   Type 2 
 
 
Number of participants        7          5               13 
Age (years; mean ± SD)                                37 ± 13                  47.4 ± 14                 49.5 ± 13.4 
Gender (%F)                86%     80%           54% 
Race (%AA)              86%     60%           77% 
Fasting Blood Glucose (mg/dl, range)             104 (72 – 135)        276 (196 – 379)       155 (71 – 277) 
Glycated Hemoglobin (%, range)            5.9 (4.9 – 7.7)               10.6 (9 – 12)            8.6 (5.9 – 13.3) 
Total Symptom Score Sum (mean ± SD)            2 ± 1.4                 4.6 ± 2.9    3.8 ± 3 
Length of Diabetes (years; mean ± SD)   N/A            33.4 ± 10.6             7.9 ± 4.2 
Age at Onset (years; mean ± SD)    N/A                   14 ± 6.4           40.8 ± 11.8 
Fasting EGG Frequency (cpm; mean ± SD)        2.57 ± .53              2.32 ± .74            2.60 ± .47 
 
Note. F = Female; AA = African American; cpm = cycles per minute.
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(SD = .53). This indicated that the sample experienced a bradygastric pattern of GMA at 
the time of the study. 
Seven healthy controls (28%) were enrolled in this study for comparison with the 
18 diabetic patients who participated. This group included 6 females (86%) and 1 male 
(14%). They ranged in age from 15 to 55 years with a mean age of 37 years (SD = 13). 
Six of the seven (86%) controls were African American. The mean fasting blood glucose 
level was 104 mg/dl. The level ranged from 72 mg/dl to 135 mg/dl (SD = 21 mg/dl). The 
mean GHB was 5.9% (range = 4.9 – 7.7%). Overall, upper GI symptoms were not 
problematic for the control group. The mean TSS sum score was 2 (SD = 1.4). The 
control group had a mean fasting EGG frequency of 2.57 cpm (SD = .53), also indicating 
that this group had bradygastric pattern of GMA. 
Five (20%) of the participants were type 1 diabetics. There were 4 female (80%), 
and 1 male (20%) in this group. They ranged in age from 30 to 70 years, with a mean age 
of 47 years (SD = 14). Three of the five (60%) were African Americans.  The mean 
fasting blood glucose level for the group was 276 mg/dl. The level ranged from 196 
mg/dl to 379 mg/dl (SD = 72 mg/dl). The mean GHB was 10.6% (range 9 – 12%).  Upper 
GI symptoms were moderate in this group with a mean TSS of 4.6 (SD = 2.9). Years of 
diabetes for the type 1 group ranged from 24 to 51 years with a mean of 33.4 years (SD = 
10.6). Age at diagnosis ranged from 5 to 20 with a mean of 14 years (SD = 6). The type 1 
diabetic subjects had a mean fasting EGG frequency of 2.37 cpm (SD = .74). This group 
had the lowest mean score, which also reflected a bradygastric pattern of GMA. 
Thirteen participants (52%) were type 2 diabetics. There were seven females 
(54%) and 6 males (46%) in this group. They ranged in age from 23 to 74 years, with a 
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mean age of 49.5 years (SD = 13.4). Ten of the thirteen (77%) were African Americans. 
The mean fasting blood glucose level was 155 mg/dl. This level ranged from 71 mg/dl to 
277 mg/dl (SD = 65 mg/dl). The mean GHB was 8.6% (range = 5.9% to 13.3%). Years of 
diabetes for the type 2 group ranged from 0.83 to 15 years with a mean of 7.9 years (SD 
= 4.2). Age at diagnosis for this group ranged from 21 to 70 with a mean 40.8 years (SD 
= 11.8). Overall, upper GI symptoms were reported as mild in this group with a mean 
TSS of 3.8 (SD = 3). The type 2 diabetic patients had a mean fasting EGG frequency of 
2.60 cpm (SD = .47). This group had a slightly better mean score than the other groups, 
but still exhibited a bradygastric pattern. 
 
Statistical Analysis of Results 
 
Research Question 1 
To answer Question 1 (What patterns of GMA can be assessed using EGG in 
patients with diabetes?) and 1a (What are the differences in patterns of GMA in healthy 
individuals versus diabetic patients?), patterns of GMA were categorized as bradygastria, 
normogastria, or tachygastria, based on previously reported methods. Subjects were 
grouped based upon whether they were diagnosed with diabetes or not, creating 2 groups: 
controls or diabetic subjects. At the end of the fasting period, 3 healthy subjects and 10 
diabetic patients exhibited bradygastria; 3 healthy subjects and 7 diabetic patients were 
normogastric; two subjects, 1 healthy subject and 1 diabetic, exhibited tachygastria. At 
the end of the 30 minute post-prandial period, 2 healthy subjects and 7 diabetic patients 
were bradygastric. Of the 8 patients with normogastria, 4 were healthy and 4 were 
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diabetic. One healthy subject and seven diabetic patients had tachygastria at the end of 
the 30 minute post-prandial period. At the end of the120 minutes post-prandial period, 2 
healthy subjects were bradygastric and 7 diabetic patients were bradygastric; 2 healthy 
subjects and 6 diabetic patients were normogastric; 3 healthy subjects and 5 diabetic 
patients were tachygastric. No significant difference in the pattern of GMA in healthy 
individuals versus diabetic patients were identified during fasting (p = .72), at 30-minutes 
post-prandial (p = .22), or 120-minutes post-prandial (p = .76). Using Fisher’s Exact test, 
non-significant p values were confirmed during the fasting (p = .14) and 120-minutes 
post-prandial periods (p = .11). A significant p value was noted at 30-minutes post-
prandial (p = .04). This suggests that no difference exist between patterns of GMA in 
healthy subjects and patients with diabetes except during the period immediately after 
eating. Table 2 summarizes these findings.   
To answer question 1b (What are the differences in patterns of GMA in patients 
with type 1 versus type 2 diabetes?), patterns of GMA were again categorized as 
bradygastria, normogastria, or tachygastria. Diabetic subjects were classified by disease 
type (1 or 2). At the end of the fasting period, 3 patients with type 1 diabetes and 7 
patients with type 2 diabetes had bradygastria. Two type 1 diabetics and 5 type 2 
diabetics had normogastria. There were no patients with type 1 diabetes with tachygastria 
at the end of the fasting period, but there was 1 patient with type 2 diabetes identified. 
Three patients with type 1 diabetes and 4 with type 2 diabetes were found to have 
bradygastria at the end of the 30 minute post-prandial period. One type 1 diabetic patient 
and 3 type 2 diabetic patients were normogastric. One patient with type 1 diabetes, and 6  
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Table 2. Patterns of Gastric Myoelectrical Activity in Healthy Controls versus 
Diabetic Patients by Testing Period 
 
  
    Frequency        Controls     Diabetic      Fisher’s p 
            n = 7        n = 18 
 
  B  3          10          .14 
Fasting N  3            7    
       T  1            1 
 
 
  B  2            7         .04* 
30-minutes N  4            4 
Post-prandial T  1            7 
 
 
  B  2            7          .11 
120-minutes N  2            6 
Post-prandial T  3            5 
 
 
Note. B = Bradygastria; N = Normogastria; T = Tachygastria. Categories do not reflect 
diagnosed gastric dysfunction. 
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with type 2 diabetes were found to be tachygastric at the end of the 30 minute post-
prandial period. At the end of the 120 minute post-prandial period, 2 type 1 patients and 
5 type 2 patients had bradygastria; 2 type 1 patients and 4 type 2 patients were 
normogastric; 1 patient with type 1 diabetes and 4 patients with type 2 diabetes were 
tachygastric. No significant differences in the pattern of GMA were identified in type 1 
versus type 2 diabetic patients during any sampling period (p = .81, .49, and .88, 
respectively). No significant p values were found when Fisher’s Exact test procedure was 
used (p = .29, .11, and, .18, respectively). Table 3 summarizes these findings. 
 
Research Question 2 
To answer Question 2 (What is the relationship of patterns of GMA with upper GI 
symptoms, acute blood glucose measurement, metabolic control, age, and length of 
diagnosis in patients with diabetes mellitus?) and 2a (What is the relationship of patterns 
of GMA with upper GI symptoms, acute blood glucose measurement, metabolic control, 
age, and length of diagnosis in patients with diabetes mellitus who are fasting?), the 
Kruskal-Wallis test of group differences was used.  Established patterns of GMA 
(bradygastria, normogastria, or tachygastria) were evaluated in relation to the diabetic 
participant’s recollection of the presence and severity of UGI signs and symptoms 
assessed using the TSS (i.e. historical symptoms), the presence and severity of UGI signs 
and symptoms during the testing procedure using a VAS, acute blood glucose 
measurement, GHB, patient age at time of study, and length of diagnosis during the 
fasting period. Variable mean scores are summarized in Table 4. At the end of the fasting 
period (time 1), there were 7 patients with normogastria, 10 with bradygastria, and 1 with  
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Table 3. Patterns of Gastric Myoelectrical Activity in Type 1 versus Type 2 Diabetic 
Patients by Testing Period 
 
 
            Type 1       Type 2      Fisher’s p 
             n = 5         n = 13 
 
  B  3           7           .29 
Fasting N  2           5    
       T  0           1 
 
  B  3           4           .11 
30-minutes N  1           3 
Post-prandial T  1           6 
 
  B  2           5           .18 
120-minutes N  2           4 
Post-prandial T  1           4 
 
Note. B = Bradygastria; N = Normogastria; T = Tachygastria.  
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Table 4. Mean Scores for Patterns of Gastric Myoelectrical Activity and Study 
Variables in Patients with Diabetes Mellitus Who Were Fasting (Period 1) 
 
    
        N             B             T  
                   n = 7         n = 10        n = 1 
Variable           Mean (± SD)           Mean (± SD)          Mean (± SD)      p 
 
  
FBG            209.7 (98.4)      178.6 (82.3)     140          .88 
GHB               9.6 (2.9)          8.8 (2.4)              9.3       .96 
Age (years)             53 (17)           47 (10)                   41             .29 
Years DM              15 (9.8)           17 (18)                5             .57 
TSS Results 
Nausea              1.4 (2.4)           4.3 (3.7)                     0            .15 
Bloating              1.7 (2.9)           3.6 (4.7)                     0      .52 
Anorexia               .7 (1.9)           1.7 (2.4)                     0           .47 
Pain               1.6 (3.0)           1.5 (2.2)                     0             .74 
Satiety                    0            3.4 (3.6)                     0  .04* 
Sum               3.4 (2.6)           4.9 (3.0)                     0       .23 
VAS Results 
Nausea                 9.29                      4.5 (11.2)           0             .87 
Vomiting                9.50                          0                           0  1.0 
Pain                 8.14                       5.5 (9.8)                      0            .39 
Bloating                8.57                    16.8 (27.7)          0             .57 
Satiety                 9.28            6.2 (19)                      0             .87 
Anorexia                8.79            9.5 (19)                      0              .66  
 
 
Note. B = Bradygastria; N = Normogastria; T = Tachygastria. FBG = Fasting Blood 
Glucose. GHB = Glycohemoglobin. Sum = Summary Score. TSS = Total Symptom 
Score (Historical Symptoms). VAS = Visual Analog Scale (Acute Symptoms).  
*p < .05. 
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tachygastria. The normogastric group had the highest mean FBG, GHB, age, and length 
of diagnosis (Years DM). The bradygastric group reported greater mean scores for  
symptom presence and severity historically and during the fasting period on all upper GI 
signs and symptoms. The tachygastric subject reported no upper GI signs and symptoms. 
During this period, satiety on the TSS scale was the only variable yielding any significant 
result (p = .04). Patients who were normogastric and those who were tachygastric 
reported equal mean scores of 6.50, while those with bradygastria had a mean score of 
11.90, indicating that subjects in the bradygastric group experienced satiety at a higher 
frequency and severity than subjects in the other groups. For this sample, no relationship 
was found between the three patterns of GMA and acute blood glucose, metabolic 
control, age, or length of diagnosis in patients with diabetes who were fasting.    
In regard to question 2b (What is the relationship of patterns of GMA with upper 
GI symptoms, acute blood glucose measurement, metabolic control, age, and length of 
diagnosis in patients with diabetes mellitus who are 30 minutes post-prandial?), summary 
statistics are shown in Table 5.  The Kruskal-Wallis test was used to answer question 2b. 
The number of patients in each category of GMA changed during the first post-prandial 
period (30 minutes post meal). During this testing period, 4 subjects were normogastric, 7 
were bradygastric, and 7 were tachygastric. The tachygastric subjects had the lowest 
mean score for acute blood glucose, GHB, and length of diagnosis, but had the highest 
mean score for age at the time of the study. The normogastric subjects reported the lowest 
mean scores nausea and for the summary score on the TSS. This group reported no other 
signs and symptoms. The bradygastric group had lower mean scores for nausea, bloating,  
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Table 5. Mean Scores for Patterns of Gastric Myoelectrical Activity and Study 
Variables in Patients with Diabetes Mellitus Who Were 30-Minutes Post Prandial 
(Period 2) 
 
    
     N           B               T  
                 n = 4               n = 7           n = 7 
Variable         Mean (± SD) Mean (± SD)     Mean (± SD)  p* 
 
 
BG           211.8 (125.8) 179.4 (67.1)    144.7 (47.9)          .47 
GHB            8.92 (3.18)     9.9 (1.7)        8.54 (2.9)          .47 
Age (years)              40 (12)      49 (14)               53 (12)              .46 
Years DM              12 (14)      20 (16)          2 (10)              .48 
TSS Results 
Nausea                  0         4.7 (4.1)        2.1 (2.7)          .21   
Bloating                  0      4.0 (5.0)        2.9 (3.6)          .28 
Anorexia                  0      1.1 (2.0)        2.0 (2.6)          .32 
Pain                   0      2.0 (2.3)        1.7 (3.1)          .22 
Satiety                   0      3.1 (3.4)        1.7 (3.4)          .18 
Sum              1.75 (1.7)     5.1 (3.0)        4.3 (2.9)          .17 
VAS Results 
Nausea                   0        5.0 (13.2)          .3 (.8)          .74 
Vomiting                  0          0        0                  1.0 
Pain                   0    7.1 (12.9)          .7 (1.9)          .20 
Bloating                  0     3.6 (9.4)        8.1 (20.7)          .49  
Satiety                   0       7 (1.9)        8.6 (22.7)          .74 
Anorexia                  0     1.4 (3.8)          .7 (1.9)            .74 
 
 
Note. B = Bradygastria; N = Normogastria; T = Tachygastria. BG = Blood Glucose. GHB 
= Glycohemoglobin. Sum = Summary Score. TSS = Total Symptom Score (Historical 
Symptoms). VAS = Visual Analog Scale (Acute Symptoms).  
*p < .05. 
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pain, satiety, and summary scores on the TSS, and lower mean scores for nausea, pain, 
and anorexia scores on the VAS than the tachygastric group. The tachygastric group had 
the highest mean scores for anorexia on the TSS, and the highest mean scores for bloating 
and satiety on the VAS. There were no significant differences found between 
distributions of scores for the patterns of GMA (Table 5).  These results indicate that 
mean scores representing the presence and severity of historical and acute UGI signs and 
symptoms, 30-minute post-prandial blood glucose, GHB, age, and length of diagnosis in 
patients with diabetes, were comparable between the three patterns of GMA.  
For question 2c (What is the relationship of patterns of GMA with upper GI 
symptoms, acute blood glucose measurement, metabolic control, age, and length of 
diagnosis in patients with diabetes mellitus who are 120 minutes post-prandial?), 
summary statistics are shown in Table 6.  The Kruskal-Wallis test was used. The number 
of patients in each category of GMA changed during this period. During period 5, 6 
subjects were normogastric, 7 were bradygastric, and 5 were tachygastric. The 
normogastric subjects had the lowest mean score for acute blood glucose. The 
bradygastric group had the lowest mean score for GHB. The normogastric group had the 
lowest mean score for age. The bradygastric group had the highest mean score for length 
of diagnosis. The normogastric subjects reported the lowest mean scores on the TSS for 
nausea, bloating, and satiety, and the highest mean scores on the VAS for pain and 
satiety. The bradygastric group had lowest mean score for pain on the TSS and reported 
no pain on the VAS. The tachygastric group had the lowest mean scores for anorexia and 
the lowest mean score for the summary score on the TSS, and the highest mean scores for  
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Table 6. Mean Scores for Patterns of Gastric Myoelectrical Activity and Study 
Variables in Patients with Diabetes Mellitus Who Were 120-Minutes Post Prandial 
(Period 5) 
 
    
  N         B                   T  
              n = 6             n = 7             n = 5 
Variable       Mean (± SD) Mean (± SD)  Mean (± SD)    p 
  
 
BG5         154 (43.3) 184 (110.9)     177 (54.9)            .69 
GHB           9.5 (1.8)        8.24 (1.9)       10 (3.8)        .62 
Age (years)           49 (12)           49 (12)        49 (18)           .81 
Years DM           19 (19)         15 (10)          10 (10)          .70 
TSS Results 
Nausea          1.8 (2.9)        4.3 (4.4)                2.4 (2.5)            .55 
Bloating          2.3 (3.7)          2.9 (4.9)         2.8 (3.9)            .98 
Anorexia          1.3 (2.1)         2.0 (2.6)              0            .26 
Pain           2.0 (2.3)             .7 (1.9)       1.8 (3.5)            .48 
Satiety            .5 (1.2)          3.7 (4.0)           1 (2.2)            .18 
Sum           3.8 (2.8)          4.4 (2.9)         3.8 (3.6)            .92 
VAS Results 
Nausea           1.7 (2.6)     9.3 (20.5)              0             .40 
Vomiting               0                  0               0                    1.00 
Pain           3.3 (5.2)           0               0                         .12 
Bloating         8.7 (17.9)   7.9 (20.7)          4 (8.9)            .49 
Satiety         11.7 (21.6)  10.7 (28.3)        20 (44.7)            .54  
Anorexia           .8 (2.0)   13.6 (35.9)               16 (35.8)             .97 
 
 
Note. B = Bradygastria; N = Normogastria; T = Tachygastria. BG = Blood Glucose. GHB 
= Glycohemoglobin; Sum = Summary Score; TSS = Total Symptom Score (Historical 
Symptoms); VAS = Visual Analog Scale (Acute Symptoms); *p < .05. 
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satiety and anorexia on the VAS. There were no significant differences found between 
the distributions of mean scores for the patterns of GMA. These results indicate that the 
scores representing the presence and severity of historical and acute upper GI signs and  
symptoms, 120-minute post-prandial blood glucose, GHB, age, and length of diagnosis in 
patients with diabetes, were comparable between the three patterns of GMA.  
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CHAPTER 5.  DISCUSSION 
 
Introduction 
Diabetes mellitus is a complex disease with multiple factors contributing to the 
inability to attain and maintain the level of glucose control necessary to reduce diabetes 
complications. Alterations in acute blood glucose levels contribute to changes in the body 
that perpetuate dysfunction. Long-term metabolic control is an essential component in the 
reduction of complications of diabetes. Alterations in the digestive process affect acute 
blood glucose levels and predispose some patients to upper GI signs and symptoms. 
Upper GI signs and symptoms are linked to altered patterns of GMA. The presence of 
upper GI signs and symptoms may prohibit the patient from ingesting appropriate 
nutrients, while the alteration in the entire digestive process prohibits the normal 
processing of nutrients and drugs required to maintain metabolic control. Damage to the 
nervous system because of chronic or acute hyperglycemia contributes to change in the 
normal pattern of GMA. Changes in the normal pattern of GMA lead to digestive system 
alterations. This vicious cycle of altered digestion and insulin-nutrient mismatch 
increases complications from diabetes.  
The identification of factors that directly influence the ability to gain metabolic 
control and the ability to describe relationships among patterns of GMA, upper GI sign 
and symptom presence and severity, and acute and long-term metabolic control in 
patients with diabetes could be used to formulate, initiate, or monitor therapeutic 
interventions. Previous studies evaluating GMA in patients with diabetes have yielded 
key information as well as conflicting results. Assessment of patterns of GMA and their 
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relationship to upper GI signs and symptoms, and acute and long-term metabolic control 
under varying conditions have been performed. Further studies are needed to generate 
data that can be used to explain the relationship between GMA abnormalities and upper 
GI signs and symptoms, lack of acute and long-term metabolic control, and increased 
diabetic complications. The aims of this research study were to assess and describe 
patterns of GMA in patients with diabetes controlling for multiple variables, and to 
determine if specific patterns of GMA corresponded with upper GI sign and symptom 
presence and severity and level of acute and long-term metabolic control in patients with 
diabetes mellitus. This chapter elaborates on the findings of this study and its limitations 
and strengths; discusses implications and recommendations for future research; and 
presents conclusions.  
 
Demographic Findings 
There were 5 patients with type 1 diabetes in the present study. This group ranged 
in age from 30 to 70 years (mean 47.4 ± 13.9), 4 of the 5 (80%) were female. Three of the 
5 (60%) were African American. Thirteen patients with type 2 diabetes participated in 
this study. This group ranged in age from 23 to 74 years (mean 49.5 ± 13.4). Seven of the 
13 subjects were female (54%). Ten of the 13 (77%) were African American. Patient 
demographics were compared with data from previous studies of GMA in patients with 
diabetes.  Eleven previous studies of GMA in patient with diabetes were reviewed. While 
the total number of participants varied greatly, overall demographic characteristics of 
study participants in the current study were consistent with other studies. In studies of 
patients with type 1 diabetes, participant numbers ranged from 6 to 57 subjects. Subjects 
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ranged in age from 22 years to 69 years. Of 183 patients with type 1 diabetes 
participating in these studies, 108 (59%) were female. Studies assessing patients with 
type 2 diabetes included 18 to 71 patients. These studies, which included a total of 155 
subjects, reported mean ages ranging from 51 years to 64 years, and had similar numbers 
of men (n = 77) and women (n = 78). Three of the previous studies were conducted in the 
United States. The other studies were completed internationally at hospitals and research 
institutes in Japan, France, Greece, Egypt, China, Germany, the Netherlands, and 
Sweden. Ethnic and racial background information was not presented in the studies 
reviewed. National Diabetes Statistics in the United States (NIDDK, 2005) report that 
there is a slight difference in the ratio of male to female incidence of diabetes, with 
10.5% of all men aged 20 years or older having diabetes, while only 8.8% of all women 
aged 20 years or older have diabetes. Non-Hispanic blacks are noted to be 1.8 times as 
likely to have diabetes as non-Hispanic whites of similar age. The current study included 
a greater female to male ratio of participants, but this discrepancy may have resulted 
because of the number of females seeking health care traditionally exceeds the rate 
reported for men (Bertakis, Azari, Helms, Callahan, & Robbins, 2000). Participants were 
primarily recruited from health care settings and were thus seeking health care. 
 
Study Aims 
 
Aim 1  
Aim 1 of this study was to characterize the patterns of gastric myoelectrical 
activity in patients with diabetes.  Electrogastrography reflects the GMA of the stomach. 
This electrical activity, measured cutaneously by electrodes placed over the abdomen, 
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provides objective information about frequency, rhythm, and power of contractions in the 
stomach. By studying EGG tracings of GMA patterns can be discerned. Recording EGG 
over time and following the feeding of subjects, allowed the investigator to the 
opportunity to identify changes in the patterns of GMA in response to a stimulus 
(feeding). Findings of this study support the potential use of EGG in the detection of 
patterns of GMA in both healthy and diabetic individuals. The availability of a quick, 
simple to use, non-invasive tool that captures objective data relative to GMA and causes 
little burden to the patient, provides the healthcare provider with data on which to base or 
modify treatment interventions if these patterns reflect associated changes in gastric 
function and symptoms. Using EGG, bradygastric, normogastric, and tachygastric 
patterns were identified in both healthy controls and patients diagnosed with diabetes. 
While the full range of patterns was present in healthy controls, these patterns were not 
interpreted as dysfunction because the EGG is not an accepted diagnostic tool. 
At the end of the initial fasting period in the present study, healthy subjects were 
either normogastric or bradygastric. Diabetic patients were also more likely to be 
bradygastric or normogastric. A shift toward normogastria occurred during the 30 minute 
post-prandial period in healthy subjects, while diabetic subjects became more 
tachygastric. This difference in the pattern of GMA was the only significant difference 
found between healthy and diabetic subjects in the current study (p = .04). At the end of 
the 120 minute post-prandial period, there were more healthy subjects exhibiting 
tachygastric patterns of GMA, while the proportion of diabetic subjects was nearly equal 
in the three categories. However, these differences in patterns of GMA were not 
statistically significant. These results are similar to results in studies conducted by  
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Mantides et al. (1997), Mathur et al. (2001), and Qi et al. (2002). These investigators 
found that bradygastria was significantly more common during the recording period and 
in particular during the fasting state and the period of meal consumption in diabetic 
patients than in controls. Additionally, in these studies the presence of normogastria did 
not increase significantly after the meal in diabetic patients as it did in controls. Also in 
diabetic patients, the dominant frequency decreased post-prandially at the spectra of 
bradygastria and normogastria, unlike the controls, who exhibited a post-prandial 
increase. 
 
Aim 2 
 Aim 2 of this study was to describe the relationships among patterns of gastric 
myoelectrical activity, gastrointestinal symptoms, and glucose control in patients with 
diabetes.  Previous studies have investigated GMA in relation to various factors 
including, glucose control, autonomic nerve function, dyspeptic symptoms, gastric 
emptying, and medication therapy. None of the studies, however, combined these 
variables in the same manner as the current study. Assessing the relationship of GMA 
with upper GI symptoms, acute blood glucose measurement, metabolic control, age, and 
length of diagnosis in patients with diabetes who were fasting, 30 minutes post-prandial, 
and 120 minutes post-prandial, while controlling for comorbid conditions affecting GI 
function and meal composition, was felt to be essential in order to support the conceptual 
framework proposed for this study and supported by published research.  
No significant relationships were identified between patterns of GMA with upper 
GI symptoms, acute blood glucose measurement, metabolic control, age, and length of 
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diagnosis in diabetic patients who were fasting, 30- or 120-minutes post-prandial. This 
finding is possibly due to the small sample size and adaptation of diabetic participants to 
chronically elevated blood glucose levels or to the presence of chronic upper GI 
symptoms. The only significant findings were the difference in patterns of GMA in 
healthy individuals versus diabetic patients at the second post-prandial period, and the 
presence and greater severity of satiety on the TSS during the fasting period for the 
diabetic group.   
Differences between patterns of GMA in healthy individuals versus diabetic 
patients were an expected finding. Persons without diagnosed diabetes, neurological, or 
other comorbid conditions affecting gastric function, i.e., healthy individuals, were not 
expected to have abnormal EGG frequencies, while the progression of nervous system 
dysfunction and altered GMA in persons with long-standing diabetes or lack of glucose 
control is reported in the literature (ADA, 2003; Joslin, 2001, NIDDK, 2003). One 
healthy subject was found to have tachygastria during the fasting and 30-minute post-
prandial periods.  This healthy individual also had elevated acute blood glucose 
measurements, an elevated GHB, and reported more acute and historical GI symptoms. 
This individual was likely an undiagnosed diabetic. Follow up with a primary care 
physician was encouraged and a referral made.  
A change in the EGG frequency would also be consistent with the normal 
response to the stomach shifting from a “fasting” to a “fed” state (Rees & Brown, 1998; 
Wingate & Phillips, 1998). This shift was apparent in both controls and diabetic subjects, 
which suggests that EGG results in this study were sensitive to this change. However, the 
PI was not blinded during interpretation of EGG tracings therefore there is the risk that 
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interpretation of study results might be biased by the knowledge of what the data 
reflected—fed versus fasting tracings.  No significant differences were identified between 
individuals with type 1 versus type 2 diabetes. This finding is consistent with the results 
of studies conducted by Kawagishi et al. (1997). 
Diabetic patients with bradygastria reported more satiety than patients who were 
normogastric or tachygastric during fasting. This finding is particularly noteworthy 
because it suggests that the EGG for diabetic patients in this study seemed to be 
appropriately sensitive to a symptom that in theory would occur in the presence of 
bradygastria. Theoretically a decrease in GMA is associated with a concomitant decrease 
in contractile activity. This decrease in the contractile activity is responsible for 
peristaltic movement of materials through the GI tract leading to gastric stasis, which 
would cause the patient to feel “full” or satiated (Malagelada & Camilleri, 1998; Redel & 
Zwiener, 1998; Wingate & Phillips, 1998). Previous studies are inconsistent in reports of 
upper GI symptoms in patients with diabetes, especially in relation to EGG patterns and 
level of glucose control (Jebbink, et al., 1994; Koch, et al., 1989; Mathur, et al., 2001; Qi, 
et al., 2002; Soykan, et al., 1999).  
 
Limitations and Strengths 
 There were several methodological limitations to this study. First, the small 
sample size decreased the power of the study and probably diminished the investigator’s 
ability to determine some statistical associations. This increased the likelihood of making 
a type II error. Secondly, the ability to analyze all aspects of the EGG tracings was 
limited by the equipment and software applications available to the investigator. The 
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development of newer EGG technology continues to make the capture and analysis of 
GMA a more valid and reliable measure. Thirdly, concurrent measurement of other 
factors associated with gastrointestinal function, such as radionucleotide gastric 
emptying, analysis of chemical and hormonal mediators affecting motility, or autonomic 
function test were not performed in this study. Completing these additional tests could 
have helped to discover how these factors contribute or affect gastric function, glucose 
control, and upper GI symptoms. Inclusion of these tests would also determine if the 
observed patterns of GMA were associated with the expected changes in gastric function. 
 Despite these methodological limitations, this study makes an important 
contribution. Assessments of GMA using EGG in relation to acute and chronic blood 
glucose measures and upper GI symptoms over time are lacking, and further exploration 
is needed to assist in clarifying the relationship between these variables.  
 
Clinical Relevance 
 The findings of this study, though tentative, could have an important impact on 
clinical practice. Patients with long-standing, poorly controlled diabetes are likely to 
experience difficulty with gastric function and report upper GI symptoms. None of the 
participants in this study had a definitive diagnosis of gastroparesis or disordered gastric 
motility. Some had undergone endoscopy or gastric emptying studies to detect the 
possible etiology for the current GI distress, but no relationship between this distress, GI 
motility, and problems with glucose management was communicated with the patient by 
their health care provider. Assessing patterns of GMA in relation to upper GI symptoms, 
glucose control, and other variables could provide additional information to help the 
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clinician treat the cause of the complaints, particularly if other more sensitive tests 
indicated associated changes in gastric function. 
Electrogastrography is an attractive alternative for assessing gastric problems and 
the etiology behind ineffective blood glucose control. The use of EGG in the clinical 
setting can provide a quick, non-invasive, inexpensive, highly tolerable test to screen and 
monitor abnormal gastric motility if patterns of GMA are associated with changes in 
gastric function. The ability to objectively determine patients who experience motility 
disturbances, and identify the type of gastric rhythm and any corresponding symptoms, 
could assist the care provider in planning and monitoring appropriate treatments.  
 
Theoretical Implications 
The study findings provided partial support for the conceptual model depicting 
relationships among acute blood glucose level, chronic blood glucose level, the presence 
and severity of upper GI signs and symptoms and patterns of GMA identified using 
electrogastrography. No direct interactions were found between GMA and levels of blood 
glucose control in the study. Patients with bradygastria and tachygastria had higher, but 
not significantly different scores for upper GI symptoms during the study, except for 
satiety in patients who were fasting. There was no association between chronic blood 
glucose levels and upper GI symptoms. Thus, further testing of the conceptual model in a 
larger sample should be undertaken because results may reflect a type II error. Future 
studies should also address previously identified limitations such as the use of more 
sophisticated EGG technology and measures of gastric function. 
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Conclusions 
Research in the area of GMA in patients with diabetes is still relatively new.  
Many aspects of this research require further investigations under controlled conditions to 
determine actual significance of the information obtained. Gastric myoelectrical activity 
has been identified as one of the variables controlling gastric motility.  
Electrogastrography has continued to develop as a tool for assessing GMA. A significant 
relationship between motility and GI symptoms has been identified in some studies, but 
not others. Diabetic patients in this study who were asymptomatic were found to have 
abnormal patterns of GMA. Healthy subjects with abnormal GMA and upper GI 
symptoms were also identified. Findings of this study support the use of EGG as a 
potential screening tool in the detection of patterns of GMA in healthy and diabetic 
individuals. The clinical utility of EGG would be confirmed if future studies document a 
clear association between gastric patterns obtained with EGG and alterations in gastric 
function obtained with invasive measures. The availability of a quick, simple to use, non-
invasive tool that captures objective data relative to GMA and causes little burden to the 
patient, provides the healthcare provider with data on which to base or modify treatment 
interventions. Using EGG, gastric myoelectrical activity can be identified in both healthy 
controls and patients diagnosed with diabetes. Further studies are needed to generate data 
that can be used to explain the pathology behind, and relationship between, GMA 
abnormalities, upper GI signs and symptoms, and the lack of glucose control in patient 
with diabetes. 
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Patient Information and Informed Consent Form 
 
Research Protocol  Gastric Myoelectrical Activity in Patients with Diabetes 
 
 
Participant’s Name  _____________________________ 
 
 
Principle Investigator: Sandra L. Holmes, RN 
    877 Madison Ave., Rm. 656 
    Memphis, TN 38163 
    (901) 448-8277 
 
Co-Investigators:  Mona Wicks, RN, PhD 
    Donna Hathaway, RN, PhD 
    Ann Cashion, RN, PhD 
     
 
 
Purpose 
You are invited to participate in the research study entitled “Gastric Myoelectrical 
Activity in Patients with Diabetes”.  You may be included in this study because you 
have been diagnosed with diabetes or as a normal healthy control.  All participants 
will undergo the same tests, whether you have diabetes or not, in order to compare 
results.  We know that complications of diabetes, such as eye, kidney, and nerve 
problems, occur because the body cannot keep normal blood sugar levels.  One of the 
reasons that some people have problems with their blood sugar is because their 
stomachs do not always work right.  When the stomach does not work like it should, 
the foods or medicines that you take do not breakdown the way that they should.  
They are also not absorbed by the intestines into the body as they should be.  
Sometimes symptoms such as nausea, vomiting, stomach pain, lack or loss of 
appetite, or bloating occur.  These symptoms make it hard for the person to eat and 
take care of him or herself.  These problems can also make it harder to keep your 
blood sugar levels normal.  We hope that this study will help us to find out more 
about how the stomach of a patient with diabetes works.  We also hope to learn how 
we can plan and monitor treatments that will help eliminate problems that cause the 
stomach to not work well. 
 
This study will use Electrogastrography (EGG) to look at how the stomach works.  
This piece of equipment works like an electrocardiograph (EKG) of the heart, 
measuring the electrical activity of the stomach through electrodes (patches) that are 
placed on the skin.  EGG has been proven to be a good test of stomach activity.  EGG 
can be completed quickly, and is tolerated well by patients.  We will use EGG in this 
study to assess stomach function. 
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Approximately 125 participants will be enrolled in this study.  This number includes 
50 patients with type 1 diabetes, 50 patients with type 2 diabetes, and 25 healthy 
volunteers.  The study will be conducted in the Center for Health Evaluation and 
Lifestyle Promotion (HELP Center) at the University of Tennessee Health Science 
Center, in Memphis, TN.  All of the information required to complete this study will 
be collected during one conveniently scheduled appointment estimated to last 3-4 
hours in the HELP Center. 
 
Procedures 
If you agree to participate in this study, you will be asked to read and sign a copy of 
this informed consent.  You will be asked to give some information about your 
current health and medical history.  You will need to come to the HELP Center to 
have your stomach test performed after fasting for at least 8 hours, and answer some 
questions about the kind and severity of stomach symptoms that you experience. You 
will also have blood samples taken from a large vein in your arm or back of the hand.   
 
Gastric (Stomach) Function Test 
The stomach test that you will have is called Electrogastrography (EGG).  This test 
detects the electrical activity of the stomach that controls the movements of the 
stomach.  The test is like the electrocardiogram (EKG) used to monitor the heart.  For 
this test, you will have EKG electrodes (patches) applied to your stomach.  Alcohol 
may be used to clean your skin and stomach hair may need to be shaved.  You will 
wear the EGG monitor for approximately 2 hours.  The first 30 minutes will be used 
to record baseline activity.  After thirty minutes, you will be provided with a standard 
meal (egg, toast, milk) to eat.  During the meal, and for the next 1½ hours, you will be 
monitored. 
 
Symptom Assessment 
You will be asked about the kind and severity of stomach symptoms (nausea, 
vomiting, stomach pain, lack or loss of appetite, and bloating) that you have 
experienced.  A short questionnaire will be used to assess symptoms that you have 
experienced over the past 2 months.  You will be asked before eating, and every 30 
minutes after you complete your meal, to rate any stomach symptoms that you have 
during the EGG test.   
 
Blood Sampling 
You will have 10 milliliters (approximately 2 teaspoonfuls) of blood drawn by an 
experienced laboratory technician to assess the level of blood sugar control that you 
have maintained over the past 2 months.  You will also have fingerstick blood sugar 
testing performed prior to beginning EGG data collection, immediately before serving 
the test meal, and every 30 minutes after eating the meal until the end of the testing 
procedure.  You may have blood drawn from an alternate site such as your forearm 
for your blood sugar test if you chose to do so. 
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Risk Associated with Participation 
You understand that there will be minimal potential risk during your participation in 
this study.  Some individuals experience skin irritation while wearing the patches and 
pain or bruising with the venipuncture that is required for obtaining blood specimens.  
You will be referred to your personal physician or to the Acute Receiving Area 
(ARA) at UT Bowld Hospital if any troubling symptoms develop during testing.  You 
will be asked to treat too low or too high blood sugar levels as you normally do based 
upon your current treatment plan or schedule.  Any new information obtained during 
this study that will affect your willingness to participate in this study will be provided 
to you.   
 
Benefits Associated with Participation 
There are no direct benefits from participating in this research study.  Potential 
benefits that you may obtain from this study are: 1) assessment of stomach activity, 2) 
identification of factors that may interfere with your ability to keep up blood sugar 
control, 3) assessment of stomach symptoms, and 4) evaluation of metabolic control.  
Information about changes in your health brought about by diabetes may help 
healthcare providers to find new ways to improve the health and lives of other 
patients.   
 
Alternative to Participation 
The alternative to participating in this study is to not participate and thereby not have 
to undergo any testing.  
 
Confidentiality 
You have the right to privacy.  All information that you provide, including medical 
history, questionnaires, laboratory findings, and physical examination will be kept 
confidential.  The information obtained will not be released to your primary care 
provider, placed in your medical records, or released to any other entity without your 
written permission.  However, representatives of the University of Tennessee Health 
Science Center Institutional Review Board and representatives of the United States 
Food and Drug Administration (FDA) may access confidential records from this 
study.   
 
Code numbers will be assigned to all data derived from this study and all information 
containing your name or other identifying information will be stored in a locked file 
cabinet and on a personal computer. The master key linking code will be maintained 
in a separate secure location. Only the research team will have access to this 
information.  The data collected during this study will be used in reports, 
presentations, and publications, but you will not be individually identified unless your 
written express consent to reveal your identity is given. 
 
Compensation and Treatment for Injury 
Every reasonable precaution will be taken to ensure your safety during the course of 
this study.  In the event that this research activity results in an injury, treatment will 
be available, including the first aid, emergency treatment, and follow-up care as 
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needed.  Payment for any such treatment must be provided by you or your third party 
payer, if any, such as insurance or Medicare. 
 
My signature on this form confirms that I understand that I am not waiving any legal 
rights or releasing the University of Tennessee of its agents from liability or 
negligence.  I understand that, in the event of physical injury resulting from the 
research procedure, the University of Tennessee does not have funds budgeted for 
compensation either for lost wages or for my medical treatment.  Therefore, the 
University does not provide for treatment or for reimbursement for such injuries.  I 
am aware that I may withdraw my consent to participate at any time and that such 
withdrawal will not restrict my access to healthcare services normally available at the 
University of Tennessee. 
 
Questions 
If you have any questions or feel that you have sustained any injury as a result of this 
study please contact Sandra Holmes (901-448-8277 or 877-346-6164 {24-hour 
pager}) or the HELP Center (901-448-1584).  If I have any questions regarding my 
rights as research subject in this study, I may call the University of Tennessee Health 
Science Center’s Institutional Review Board Chair, Clair E. Cox, MD (901-448-
4824).  My signature below means that I have freely agreed to participate in this study 
and I have received a copy of this consent form for my records. 
 
Payment for Participation 
I will be paid $25.00 for completing this study.  Payment will not be rendered if I do 
not complete all parts of the research protocol.  If I am a minor, payment will be 
made to me in care of my parent or guardian. 
 
Cost of Participation 
I will incur no charges for participating in this study.  The investigator will provide 
funds to pay for all services required for completion of this study. 
 
Premature Termination 
In the event that I decide not to participate in this study, I will notify Ms. Holmes.  I 
understand that I may withdraw from the study at any time and will continue to 
receive standard treatment. 
 
Voluntary Participation 
I understand that I am not required to participate in this study and that I a free to 
refuse to participate in the study or withdraw from the study at any time.  My 
decisions will not affect my care at this institution and I will not be penalized or lose 
any benefits to which I am entitled. 
 
Consent of Subject 
I have read or have had read to me the description of the study as outlined above.  
The investigator or his/her representative has explained the study to me and has 
answered all of the questions I have at this time.  I have been told of the potential risk, 
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discomforts, side effects, and adverse reactions, as well as the possible benefits (if 
any) of the study.  I freely volunteer to participate in this study.  I understand that I do 
not have to take part in this study and that my refusal to participate will involve no 
penalty or loss of rights to which I am entitled.  I further understand that I am free to 
withdraw from this study at any time.  I understand that refusing to participate or later 
withdrawing from this study will not adversely affect the subsequent medical care 
that I receive. 
 
 
 
_________________________________  ________________________ 
Signature of Research Subject or Legally Date 
Authorized Representative 
 
_____________________________   ________________________ 
Signature of Witness    Date 
 
_____________________________   ________________________ 
Signature of Person Obtaining Consent  Date 
 
_____________________________   ________________________ 
Signature of Principal Investigator  Date 
 
_____________________________   ________________________ 
Assent of Minor     Date 
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Patient Data Sheet 
 
EGG Study 
Date ________________ 
 
Name _____________________________________________  SSN ________________ 
 First   MI.   Last  
Date of Birth __________________  Age _____  Gender: Male ___  Female ____ 
  Month/Day/Year 
Race:  Caucasian ___  African-American ____  Hispanic _____  Other (specify) ____ 
Address________________________________________________________________ 
City ___________________________  State ______  Zip __________ 
Telephone # ____________________ Emergency Contact # _____________________ 
Marital Status: Single ____  Married _____  Divorced _____  Widow(er) _____ 
Highest Level of Education (circle one): Grade <6  6  7  8  9  10  11  12  College  1  2  3  4  + 
Degrees _________________ 
Employment Status:  Fulltime ___  Part-time ___  Retired ___  Disabled ___  Unemployed ____ 
Occupation ______________________ 
Smoke?  Y    N    Number of cigarettes per day ___ Number of Years ___  Pack/Years ____ 
Allergies? ____________________________________________________________________ 
Do you have or have you had any of the following diseases or conditions: 
High Blood Pressure _______ Stroke _______ Heart Attack ______ 
Angina ______ Heart Failure _____  Sickle Cell Disease ______ 
Cancer ______ Kidney Problems _____ Lung Problems ______ 
Bleeding Problems _____ Liver Problems ______ Psychiatric Problems _____ 
Seizures _____ Peptic Ulcer Disease _____ Gastroesophageal Reflux Disease _____ 
Pancreatitis _____ Uremia _____ Crohn’s Disease _____ Ulcerative Colitis _____ 
Irritable Bowel Disease _____ Lactose Intolerance _____ Anorexia Nervosa _____ 
Bulimia _____  Type 1 Diabetes _____ Type 2 Diabetes _____ 
Years DM _____  Age at Diagnosis _____Last Menstrual Period _____________ 
Current Medications 
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________ 
 
HT ____    WT _____     BP____   Time of Last Meal ____     Fasting Blood Glucose _____ 
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Flow Diagram of Testing Procedure  
 
Participant recruited 
Study reviewed and testing date scheduled 
 
Testing Day 
Verify fasting status, taking of regularly prescribed meds (except GI meds previously indicated) 
 
Obtained informed consent 
Collect demographic data, complete symptom assessment (TSS), obtain blood sample 
Perform blood glucose monitoring 
Direct to restroom 
Positioned in recliner 
Complete symptom assessment (VAS) 
EGG electrodes attached 
Record EGG in fasting state for 30 minutes 
 
Perform blood glucose monitoring 
 
Complete symptom assessment (VAS) 
Provide meal 
 
Record first post-prandial period (30 minutes) 
Perform blood glucose monitoring 
 
Complete symptom assessment (VAS) 
Record second post-prandial period 
 
Perform blood glucose monitoring 
Complete symptom assessment (VAS) 
 
Record third post-prandial period 
         Perform blood glucose monitoring 
 
Complete symptom assessment (VAS) 
Indicate end of testing procedure
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Study Number ____ 
 
VAS  
 
 
VAS#: ____  Time: ____ 
 
Comments: _____________________________________________________ 
 
 
VAS Scale: 
 
 Worst Possible Nausea 100 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 No Nausea     0 
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Study Number ____ 
 
VAS 
 
 
VAS#: ____  Time: ____ 
 
Comments: _____________________________________________________ 
 
 
VAS Scale: 
 
 Worst Possible Bloating 100 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 No Bloating     0 
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Study Number ____ 
 
VAS 
 
 
VAS#: ____  Time: ____ 
 
Comments: _____________________________________________________ 
 
 
VAS Scale: 
 
 Worst Possible Vomiting 100 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 No Vomiting     0 
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Study Number ____ 
 
VAS 
 
 
VAS#: ____  Time: ____ 
 
Comments: _____________________________________________________ 
 
 
VAS Scale: 
 
 Worst Possible Pain  100 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 No Pain     0 
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Study Number ____ 
 
VAS 
 
 
VAS#: ____  Time: ____ 
 
Comments: _____________________________________________________ 
 
 
VAS Scale: 
 
 Worst Possible Satiety 100 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 No Satiety     0 
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Study Number ____ 
 
VAS 
 
 
VAS#: ____  Time: ____ 
 
Comments: _____________________________________________________ 
 
 
VAS Scale: 
 
 Worst Possible Anorexia 100 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 No Anorexia     0 
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UT/UTMG “GI” Symptom Scale 
Project: Gastric Myoelectrical Activity in Patients with Diabetes 
 
Study Number: ____       Date: _________ 
The Investigator ask the patient for the overall intensity of each listed symptom on a 
scale of 0 – 10, where 0 is best and 10 is worst. 
 
        Best                             Worst 
Symptom   No  Yes             Circle ONE Number 
 
Did the patient have  ___  ___    0  1  2  3  4  5  6  7  8  9  10 
Nausea (feel sick to 
His/her stomach)? 
 
Did the patient have  ___  ___    0  1  2  3  4  5  6  7  8  9  10 
Bloating/distention  
(loosen clothes after 
eating)? 
 
Did the patient have  ___  ___    0  1  2  3  4  5  6  7  8  9  10 
Anorexia (poor appetite)? 
 
Did the patient have  ___  ___    0  1  2  3  4  5  6  7  8  9  10 
Abdominal Pain? 
 
Did the patient have  ___  ___    0  1  2  3  4  5  6  7  8  9  10 
Satiety (feel full 
early)? 
 
 
OVERALL PATIENT ASSESSMENT 
 
 
On a 0 1- scale, how       0  1  2  3  4  5  6  7  8  9  10 
did the patient feel  
during the past 2  
months overall? 
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